<?xml version="1.0" encoding="UTF-8"?>
<patent-document ucid="EP-1614678-B1" country="EP" doc-number="1614678" kind="B1" date="20140101" family-id="26047263" file-reference-id="311081" date-produced="20180822" status="corrected" lang="EN"><bibliographic-data><publication-reference fvid="146553850" ucid="EP-1614678-B1"><document-id><country>EP</country><doc-number>1614678</doc-number><kind>B1</kind><date>20140101</date><lang>EN</lang></document-id></publication-reference><application-reference ucid="EP-05021577-A" is-representative="NO"><document-id mxw-id="PAPP154827773" load-source="docdb" format="epo"><country>EP</country><doc-number>05021577</doc-number><kind>A</kind><date>19990625</date><lang>EN</lang></document-id><document-id mxw-id="PAPP232907702" load-source="docdb" format="original"><country>EP</country><doc-number>05021577.1</doc-number><date>19990625</date></document-id></application-reference><priority-claims><priority-claim mxw-id="PPC140446807" ucid="DE-19830430-A" load-source="docdb"><document-id format="epo"><country>DE</country><doc-number>19830430</doc-number><kind>A</kind><date>19980708</date></document-id></priority-claim><priority-claim mxw-id="PPC140448882" ucid="DE-19903126-A" load-source="docdb"><document-id format="epo"><country>DE</country><doc-number>19903126</doc-number><kind>A</kind><date>19990127</date></document-id></priority-claim><priority-claim mxw-id="PPC140454318" ucid="EP-99929318-A" linkage-type="3" load-source="docdb"><document-id format="epo"><country>EP</country><doc-number>99929318</doc-number><kind>A</kind><date>19990625</date></document-id></priority-claim></priority-claims><dates-of-public-availability><intention-to-grant-date><date>20130719</date></intention-to-grant-date></dates-of-public-availability><technical-data><classifications-ipcr><classification-ipcr mxw-id="PCL1988096209" load-source="docdb">A61K  31/42        20060101ALI20051117BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988096268" load-source="docdb">A61K  31/5377      20060101ALI20051220RMJP        </classification-ipcr><classification-ipcr mxw-id="PCL1988096498" load-source="docdb">C07D 209/14        20060101ALI20051220RMJP        </classification-ipcr><classification-ipcr mxw-id="PCL1988096840" load-source="docdb">A61K  31/38        20060101ALI20051117BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988097563" load-source="docdb">C07D 233/84        20060101A I20051008RMEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988098317" load-source="docdb">C07D 261/16        20060101ALI20051117BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988098755" load-source="docdb">C07C 323/60        20060101A I20051008RMEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988098756" load-source="docdb">C07D 207/48        20060101A I20051008RMEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988098767" load-source="docdb">A61K  31/4725      20060101ALI20051220RMJP        </classification-ipcr><classification-ipcr mxw-id="PCL1988099104" load-source="docdb">A61K  31/435       20060101ALI20051220RMJP        </classification-ipcr><classification-ipcr mxw-id="PCL1988099156" load-source="docdb">C07C 317/40        20060101ALI20051117BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988099188" load-source="docdb">C07D 277/54        20060101A I20051008RMEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988099519" load-source="docdb">A61K  31/275       20060101ALI20051220RMJP        </classification-ipcr><classification-ipcr mxw-id="PCL1988100328" load-source="docdb">C07D 213/82        20060101ALI20051220RMJP        </classification-ipcr><classification-ipcr mxw-id="PCL1988100439" load-source="docdb">C07D 243/08        20060101A I20051008RMEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988101026" load-source="docdb">C07D 295/26        20060101A I20051008RMEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988101031" load-source="docdb">A61K  31/4439      20060101ALI20051220RMJP        </classification-ipcr><classification-ipcr mxw-id="PCL1988101394" load-source="docdb">A61K  31/4545      20060101ALI20051220RMJP        </classification-ipcr><classification-ipcr mxw-id="PCL1988101506" load-source="docdb">C07D 233/42        20060101ALI20051220RMJP        </classification-ipcr><classification-ipcr mxw-id="PCL1988103025" load-source="docdb">A61P   9/04        20060101ALI20051220RMJP        </classification-ipcr><classification-ipcr mxw-id="PCL1988103662" load-source="docdb">A61K  31/4184      20060101ALI20051220RMJP        </classification-ipcr><classification-ipcr mxw-id="PCL1988103941" load-source="docdb">A61K  31/4535      20060101ALI20051220RMJP        </classification-ipcr><classification-ipcr mxw-id="PCL1988104719" load-source="docdb">A61K  31/428       20060101ALI20051220RMJP        </classification-ipcr><classification-ipcr mxw-id="PCL1988105308" load-source="docdb">C07C 323/42        20060101ALI20051117BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988105472" load-source="docdb">A61K  31/454       20060101ALI20051220RMJP        </classification-ipcr><classification-ipcr mxw-id="PCL1988105638" load-source="docdb">A61K  31/4409      20060101ALI20051220RMJP        </classification-ipcr><classification-ipcr mxw-id="PCL1988105937" load-source="docdb">A61K  31/404       20060101ALI20051220RMJP        </classification-ipcr><classification-ipcr mxw-id="PCL1988106422" load-source="docdb">C07C 311/46        20060101A I20051008RMEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988106431" load-source="docdb">A61P   1/16        20060101ALI20051220RMJP        </classification-ipcr><classification-ipcr mxw-id="PCL1988106758" load-source="docdb">A61K  31/5355      20060101ALI20051220RMJP        </classification-ipcr><classification-ipcr mxw-id="PCL1988107016" load-source="docdb">A61P  43/00        20060101ALI20051220RMJP        </classification-ipcr><classification-ipcr mxw-id="PCL1988107486" load-source="docdb">C07D 239/42        20060101A I20051008RMEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988107771" load-source="docdb">A61P   9/12        20060101ALI20051220RMJP        </classification-ipcr><classification-ipcr mxw-id="PCL1988108005" load-source="docdb">C07D 239/06        20060101A I20051008RMEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988108663" load-source="docdb">A61P  13/12        20060101ALI20051220RMJP        </classification-ipcr><classification-ipcr mxw-id="PCL1988108833" load-source="docdb">A61P   9/00        20060101ALI20051220RMJP        </classification-ipcr><classification-ipcr mxw-id="PCL1988108886" load-source="docdb">C07D 213/42        20060101ALI20051220RMJP        </classification-ipcr><classification-ipcr mxw-id="PCL1988108902" load-source="docdb">C07D 209/10        20060101A I20051008RMEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988109996" load-source="docdb">C07D 277/04        20060101A I20051008RMEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988110033" load-source="docdb">C07D 235/18        20060101A I20051008RMEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988110870" load-source="docdb">A61K  31/5375      20060101ALI20051220RMJP        </classification-ipcr><classification-ipcr mxw-id="PCL1988111021" load-source="docdb">C07D 231/18        20060101A I20051008RMEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988111193" load-source="docdb">A61P   9/10        20060101ALI20051220RMJP        </classification-ipcr><classification-ipcr mxw-id="PCL1988111737" load-source="docdb">C07C 311/21        20060101A I20051008RMEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988111738" load-source="docdb">C07D 333/38        20060101A I20051008RMEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988113559" load-source="docdb">A61K  31/44        20060101ALI20051117BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988113991" load-source="docdb">A61P   7/02        20060101ALI20051220RMJP        </classification-ipcr><classification-ipcr mxw-id="PCL1988114091" load-source="docdb">A61K  31/445       20060101ALI20051220RMJP        </classification-ipcr><classification-ipcr mxw-id="PCL1988114383" load-source="docdb">C07D 207/12        20060101A I20051008RMEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988114403" load-source="docdb">C07D 295/08        20060101ALI20051220RMJP        </classification-ipcr><classification-ipcr mxw-id="PCL1988115108" load-source="docdb">C07D 215/36        20060101A I20051008RMEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988116273" load-source="docdb">A61P   9/02        20060101ALI20051220RMJP        </classification-ipcr><classification-ipcr mxw-id="PCL1988116522" load-source="docdb">A61P   3/10        20060101ALI20051220RMJP        </classification-ipcr><classification-ipcr mxw-id="PCL1988116542" load-source="docdb">C07C 323/41        20060101AFI20051117BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988117603" load-source="docdb">A61K  31/4402      20060101ALI20051220RMJP        </classification-ipcr><classification-ipcr mxw-id="PCL1988117972" load-source="docdb">C07D 221/20        20060101ALI20051220RMJP        </classification-ipcr><classification-ipcr mxw-id="PCL1988118071" load-source="docdb">A61K  31/381       20060101ALI20051220RMJP        </classification-ipcr><classification-ipcr mxw-id="PCL1988119453" load-source="docdb">A61K  31/4166      20060101ALI20051220RMJP        </classification-ipcr><classification-ipcr mxw-id="PCL1988119880" load-source="docdb">C07D 277/20        20060101ALI20051220RMJP        </classification-ipcr><classification-ipcr mxw-id="PCL1988120041" load-source="docdb">A61K  31/541       20060101ALI20051220RMJP        </classification-ipcr><classification-ipcr mxw-id="PCL1988120123" load-source="docdb">C07D 333/34        20060101ALI20051117BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988120613" load-source="docdb">C07C 331/12        20060101A I20051008RMEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988120851" load-source="docdb">A61K  31/4433      20060101ALI20051220RMJP        </classification-ipcr><classification-ipcr mxw-id="PCL1988121187" load-source="docdb">A61K  31/54        20060101ALI20051220RMJP        </classification-ipcr><classification-ipcr mxw-id="PCL1988121645" load-source="docdb">C07C 323/52        20060101A I20051008RMEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988122153" load-source="docdb">A61K  31/496       20060101ALI20051220RMJP        </classification-ipcr><classification-ipcr mxw-id="PCL1988122762" load-source="docdb">C07D 295/22        20060101ALI20051117BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988123341" load-source="docdb">A61K  31/4462      20060101ALI20051220RMJP        </classification-ipcr><classification-ipcr mxw-id="PCL1988123869" load-source="docdb">C07D 207/16        20060101A I20051008RMEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988124021" load-source="docdb">A61K  31/401       20060101ALI20051220RMJP        </classification-ipcr><classification-ipcr mxw-id="PCL1988124419" load-source="docdb">A61P  11/06        20060101ALI20051220RMJP        </classification-ipcr><classification-ipcr mxw-id="PCL1988125073" load-source="docdb">C07D 211/54        20060101ALI20051220RMJP        </classification-ipcr><classification-ipcr mxw-id="PCL1988126047" load-source="docdb">C07D 413/12        20060101ALI20051220RMJP        </classification-ipcr><classification-ipcr mxw-id="PCL1988126261" load-source="docdb">C07D 277/36        20060101A I20051008RMEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988126567" load-source="docdb">A61K  31/40        20060101ALI20051220RMJP        </classification-ipcr><classification-ipcr mxw-id="PCL1988126584" load-source="docdb">A61K  31/495       20060101ALI20051220RMJP        </classification-ipcr><classification-ipcr mxw-id="PCL1988126896" load-source="docdb">C07D 333/70        20060101ALI20051220RMJP        </classification-ipcr><classification-ipcr mxw-id="PCL1988126924" load-source="docdb">C07D 231/42        20060101A I20051008RMEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988127644" load-source="docdb">A61P  15/10        20060101ALI20051220RMJP        </classification-ipcr><classification-ipcr mxw-id="PCL1988127848" load-source="docdb">C07D 235/28        20060101ALI20051117BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988128041" load-source="docdb">C07C 311/51        20060101A I20051008RMEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988128144" load-source="docdb">A61K  31/415       20060101ALI20051220RMJP        </classification-ipcr><classification-ipcr mxw-id="PCL1988129123" load-source="docdb">A61K  31/426       20060101ALI20051220RMJP        </classification-ipcr><classification-ipcr mxw-id="PCL1988129827" load-source="docdb">C07D 213/78        20060101A I20051008RMEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988130018" load-source="docdb">A61K  31/4427      20060101ALI20051220RMJP        </classification-ipcr><classification-ipcr mxw-id="PCL1988130482" load-source="docdb">A61K  31/506       20060101ALI20051220RMJP        </classification-ipcr><classification-ipcr mxw-id="PCL1988130740" load-source="docdb">A61P  25/28        20060101ALI20051220RMJP        </classification-ipcr><classification-ipcr mxw-id="PCL1988131517" load-source="docdb">C07D 333/62        20060101ALI20051220RMJP        </classification-ipcr><classification-ipcr mxw-id="PCL1988132484" load-source="docdb">C07D 213/71        20060101A I20051008RMEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988132487" load-source="docdb">C07D 277/46        20060101ALI20051117BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988132544" load-source="docdb">C07C 311/58        20060101A I20051008RMEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988133179" load-source="docdb">C07D 333/40        20060101A I20051008RMEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988133724" load-source="docdb">A61K  31/4453      20060101ALI20051220RMJP        </classification-ipcr><classification-ipcr mxw-id="PCL1988134824" load-source="docdb">A61K  31/403       20060101ALI20051220RMJP        </classification-ipcr><classification-ipcr mxw-id="PCL1988135248" load-source="docdb">C07D 277/64        20060101A I20051008RMEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988135486" load-source="docdb">A61K  31/551       20060101ALI20051220RMJP        </classification-ipcr><classification-ipcr mxw-id="PCL1988135540" load-source="docdb">A61K  31/4436      20060101ALI20051220RMJP        </classification-ipcr><classification-ipcr mxw-id="PCL1988136097" load-source="docdb">C07D 213/80        20060101A I20051008RMEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988136681" load-source="docdb">C07D 401/12        20060101A I20051008RMEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988137069" load-source="docdb">C07D 265/30        20060101ALI20051220RMJP        </classification-ipcr><classification-ipcr mxw-id="PCL1988137708" load-source="docdb">C07D 277/10        20060101ALI20051220RMJP        </classification-ipcr><classification-ipcr mxw-id="PCL1988138187" load-source="docdb">A61K  31/18        20060101ALI20051117BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988138219" load-source="docdb">C07D 261/10        20060101A I20051008RMEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988138455" load-source="docdb">C07D 409/12        20060101ALI20051220RMJP        </classification-ipcr><classification-ipcr mxw-id="PCL1988138794" load-source="docdb">C07D 211/96        20060101ALI20051117BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988139107" load-source="docdb">A61K  31/505       20060101ALI20051220RMJP        </classification-ipcr></classifications-ipcr><classifications-cpc><classification-cpc mxw-id="PCL-1815470189" load-source="docdb" scheme="CPC">C07D 213/71        20130101 LI20170506BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1815470684" load-source="docdb" scheme="CPC">C07D 277/04        20130101 LI20170506BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1815470977" load-source="docdb" scheme="CPC">C07D 261/16        20130101 LI20170506BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1815471238" load-source="docdb" scheme="CPC">C07D 491/10        20130101 LI20170506BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1815471999" load-source="docdb" scheme="CPC">C07D 333/40        20130101 LI20170506BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1815472482" load-source="docdb" scheme="CPC">C07D 211/46        20130101 LI20170506BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1815473053" load-source="docdb" scheme="CPC">C07D 231/18        20130101 LI20170506BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1815474077" load-source="docdb" scheme="CPC">C07D 211/96        20130101 LI20170506BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1815474351" load-source="docdb" scheme="CPC">C07D 231/42        20130101 LI20170506BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1815474442" load-source="docdb" scheme="CPC">C07D 279/12        20130101 LI20170506BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1815475027" load-source="docdb" scheme="CPC">C07D 209/14        20130101 LI20170506BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1815476741" load-source="docdb" scheme="CPC">C07D 213/80        20130101 LI20170506BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1815478454" load-source="docdb" scheme="CPC">C07D 207/16        20130101 LI20170506BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1815478690" load-source="docdb" scheme="CPC">C07D 239/42        20130101 LI20170506BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1815479551" load-source="docdb" scheme="CPC">C07D 233/84        20130101 LI20170506BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1815479731" load-source="docdb" scheme="CPC">C07D 213/78        20130101 LI20170506BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1815481869" load-source="docdb" scheme="CPC">C07C 323/60        20130101 LI20170506BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1815483172" load-source="docdb" scheme="CPC">C07D 207/12        20130101 LI20170506BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1815483922" load-source="docdb" scheme="CPC">C07C 311/46        20130101 LI20170506BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1815484676" load-source="docdb" scheme="CPC">C07D 207/48        20130101 LI20170506BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1815485307" load-source="docdb" scheme="CPC">C07D 295/26        20130101 LI20170506BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1815485665" load-source="docdb" scheme="CPC">C07C 323/52        20130101 LI20170506BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1815485809" load-source="docdb" scheme="CPC">C07D 235/18        20130101 LI20170506BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1815485908" load-source="docdb" scheme="CPC">C07D 333/38        20130101 LI20170506BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1815486379" load-source="docdb" scheme="CPC">C07D 401/12        20130101 LI20170506BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1815486929" load-source="docdb" scheme="CPC">C07D 333/34        20130101 LI20170506BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1815487732" load-source="docdb" scheme="CPC">C07D 231/38        20130101 LI20170506BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1815488661" load-source="docdb" scheme="CPC">C07D 243/08        20130101 LI20170506BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1815489998" load-source="docdb" scheme="CPC">C07D 239/06        20130101 LI20170506BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1815490946" load-source="docdb" scheme="CPC">C07C 331/12        20130101 LI20170506BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1815491163" load-source="docdb" scheme="CPC">C07D 413/12        20130101 LI20170506BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1815491201" load-source="docdb" scheme="CPC">C07D 215/36        20130101 LI20170506BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1815491321" load-source="docdb" scheme="CPC">C07D 209/10        20130101 LI20170506BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1815492389" load-source="docdb" scheme="CPC">C07C 323/42        20130101 LI20170506BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1815492554" load-source="docdb" scheme="CPC">C07D 277/54        20130101 LI20170506BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1815493274" load-source="docdb" scheme="CPC">C07D 277/52        20130101 LI20170506BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1815493363" load-source="docdb" scheme="CPC">C07C 311/51        20130101 LI20170506BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1815493721" load-source="docdb" scheme="CPC">C07D 221/20        20130101 LI20170506BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1815494149" load-source="docdb" scheme="CPC">C07D 265/30        20130101 LI20170506BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1815494292" load-source="docdb" scheme="CPC">C07D 277/46        20130101 LI20170506BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1815494593" load-source="docdb" scheme="CPC">C07D 211/54        20130101 LI20170506BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1815494900" load-source="docdb" scheme="CPC">C07D 261/10        20130101 LI20170506BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1815495028" load-source="docdb" scheme="CPC">C07D 211/62        20130101 LI20170506BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1815495212" load-source="docdb" scheme="CPC">C07D 277/36        20130101 LI20170506BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1815495450" load-source="docdb" scheme="CPC">C07D 207/20        20130101 LI20170506BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1815495725" load-source="docdb" scheme="CPC">C07C 311/21        20130101 FI20170506BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1815496441" load-source="docdb" scheme="CPC">C07C 317/40        20130101 LI20170506BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1815496649" load-source="docdb" scheme="CPC">C07D 277/64        20130101 LI20170506BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1815497532" load-source="docdb" scheme="CPC">C07C 311/58        20130101 LI20170506BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1815498320" load-source="docdb" scheme="CPC">C07D 239/26        20130101 LI20170506BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1815498629" load-source="docdb" scheme="CPC">C07D 213/82        20130101 LI20170506BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1820284827" load-source="docdb" scheme="CPC">C07C2602/04        20170501 LA20170503BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1820284828" load-source="docdb" scheme="CPC">C07C2602/08        20170501 LA20170503BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1820284829" load-source="docdb" scheme="CPC">C07C2601/14        20170501 LA20170502BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1820284830" load-source="docdb" scheme="CPC">C07C2601/02        20170501 LA20170502BHEP        </classification-cpc></classifications-cpc><invention-title mxw-id="PT132194034" lang="DE" load-source="patent-office">Schwefel-substituierte Sulfonylaminocarbonsäure-N-heteroarylamide, ihre Herstellung, ihre Anwendung und diese enthaltende pharmazeutische Zusammensetzungen</invention-title><invention-title mxw-id="PT132194035" lang="EN" load-source="patent-office">Sulfur substituted sulfonylaminocarboxylic acid N-heteroarylamides, their preparation, their use and pharmaceutical preparations comprising them</invention-title><invention-title mxw-id="PT132194036" lang="FR" load-source="patent-office">N-heteroarylamides d'acide sulfonylaminocarboxylique à substitution soufre, preparation et utilisation de ces derniers et preparations pharmaceutiques contenant ces composés</invention-title></technical-data><related-documents><relation type="division"><child-doc ucid="EP-05021577-A"><document-id load-source="patent-office" format="epo"><country>EP</country><doc-number>05021577</doc-number><kind>A</kind><date>19990625</date></document-id></child-doc><parent-doc ucid="EP-99929318.6"><document-id load-source="patent-office" format="epo"><country>EP</country><doc-number>99929318.6</doc-number><date>19990625</date></document-id></parent-doc></relation></related-documents><parties><applicants><applicant mxw-id="PPAR918157243" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>SANOFI AVENTIS DEUTSCHLAND</last-name><address><country>DE</country></address></addressbook></applicant><applicant mxw-id="PPAR918170944" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>SANOFI-AVENTIS DEUTSCHLAND GMBH</last-name></addressbook></applicant></applicants><inventors><inventor mxw-id="PPAR918144120" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>SCHINDLER URSULA</last-name><address><country>DE</country></address></addressbook></inventor><inventor mxw-id="PPAR918133314" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>SCHINDLER, URSULA</last-name></addressbook></inventor><inventor mxw-id="PPAR918998173" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>SCHINDLER, URSULA</last-name><address><street>Robert-Stolz-Strasse 56</street><city>65812 Bad Soden</city><country>DE</country></address></addressbook></inventor><inventor mxw-id="PPAR918151310" load-source="docdb" sequence="2" format="epo"><addressbook><last-name>SCHOENAFINGER KARL</last-name><address><country>DE</country></address></addressbook></inventor><inventor mxw-id="PPAR918152261" load-source="docdb" sequence="2" format="intermediate"><addressbook><last-name>SCHOENAFINGER, KARL</last-name></addressbook></inventor><inventor mxw-id="PPAR918998175" load-source="patent-office" sequence="2" format="original"><addressbook><last-name>Schönafinger, Karl </last-name><address><street>Holunderweg 8</street><city>63755 Alzenau</city><country>DE</country></address></addressbook></inventor><inventor mxw-id="PPAR918153597" load-source="docdb" sequence="3" format="epo"><addressbook><last-name>STROBEL HARTMUT</last-name><address><country>DE</country></address></addressbook></inventor><inventor mxw-id="PPAR918158228" load-source="docdb" sequence="3" format="intermediate"><addressbook><last-name>STROBEL, HARTMUT</last-name></addressbook></inventor><inventor mxw-id="PPAR918998174" load-source="patent-office" sequence="3" format="original"><addressbook><last-name>STROBEL, HARTMUT</last-name><address><street>Erlenweg 22</street><city>65835 Liederbach</city><country>DE</country></address></addressbook></inventor></inventors><assignees><assignee mxw-id="PPAR918998176" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Sanofi-Aventis Deutschland GmbH</last-name><iid>100742863</iid><address><street>Brüningstrasse 50</street><city>65929 Frankfurt am Main</city><country>DE</country></address></addressbook></assignee></assignees></parties><international-convention-data><designated-states><ep-contracting-states><country mxw-id="DS548990662" load-source="docdb">AT</country><country mxw-id="DS548830275" load-source="docdb">BE</country><country mxw-id="DS548868208" load-source="docdb">CH</country><country mxw-id="DS548987270" load-source="docdb">CY</country><country mxw-id="DS548980406" load-source="docdb">DE</country><country mxw-id="DS548830276" load-source="docdb">DK</country><country mxw-id="DS548980855" load-source="docdb">ES</country><country mxw-id="DS548983239" load-source="docdb">FI</country><country mxw-id="DS548983240" load-source="docdb">FR</country><country mxw-id="DS548980407" load-source="docdb">GB</country><country mxw-id="DS548830277" load-source="docdb">GR</country><country mxw-id="DS548868209" load-source="docdb">IE</country><country mxw-id="DS548983241" load-source="docdb">IT</country><country mxw-id="DS548987271" load-source="docdb">LI</country><country mxw-id="DS548990663" load-source="docdb">LU</country><country mxw-id="DS548980408" load-source="docdb">MC</country><country mxw-id="DS548980856" load-source="docdb">NL</country><country mxw-id="DS548990664" load-source="docdb">PT</country><country mxw-id="DS548980857" load-source="docdb">SE</country></ep-contracting-states></designated-states></international-convention-data></bibliographic-data><description mxw-id="PDES63957468" lang="EN" load-source="patent-office"><!-- EPO <DP n="1"> --><p id="p0001" num="0001">The present invention relates to compounds of the formula I
<chemistry id="chem0001" num="0001"><img id="ib0001" file="imgb0001.tif" wi="82" he="64" img-content="chem" img-format="tif"/></chemistry>
wherein A<sup>1</sup>, A<sup>2</sup>, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, X and n are as defined below, which are valuable pharmaceutically active compounds for the therapy and prophylaxis of diseases, for example of cardiovascular diseases such as hypertension, angina pectoris, cardiac insufficiency, thromboses or atherosclerosis. The compounds of the formula I are capable of modulating the body's production of cyclic guanosine monophosphate (cGMP) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of the formula I, to their use for the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of the formula I.<!-- EPO <DP n="2"> --> cGMP is an important intracellular messenger which triggers a multitude of different effects via the modulation of cGMP-dependent protein kinases, phosphodiesterases and ion channels. Examples are the relaxation of smooth muscles, the inhibition of thrombocyte activation and the inhibition of the proliferation of smooth-muscle cells and of leukocyte adhesion. cGMP is produced by particulate and soluble guanylate cyclases as a response to a number of extracellular and intracellular stimuli. In the case of the particulate guanylate cyclases, stimulation is essentially effected by peptidic messengers, such as the atrial natriuretic peptide or the cerebral natriuretic peptide. The soluble guanylate cyclases (sGC), which are cytosolic heterodimeric heme proteins, in contrast, are essentially regulated by a family of low-molecular weight factors which are formed enzymatically. The most important stimulant is nitrogen monoxide (NO) or a closely related species. The function of other factors such as carbon monoxide or the hydroxyl radical is still largely unclear. Binding of NO to the heme with formation of a penta-coordinate heme-nitrosyl complex is being discussed as activation mechanism of the activation by NO. The associated release of the histidine which is bound in the basal state to the iron converts the enzyme into the active conformation.</p><p id="p0002" num="0002">Active soluble guanylate cyclases are composed of an α and a β subunit each. Several subunit subtypes have been described which differ from one another with respect to sequence, tissue-specific distribution and expression in different development stages. The subtypes α<sub>1</sub> and β<sub>1</sub> are mainly expressed in brain and lung, while β<sub>2</sub> is found in particular in liver and kidney. The subtype α<sub>2</sub> was shown to be present in human fetal brain. The subunits referred to as α<sub>3</sub> and β<sub>3</sub> were isolated from human brain and are homologous to α<sub>1</sub> and β<sub>1</sub>. More recent works indicate an α <sub>2i</sub> subunit which contains an insert in the catalytic domain. All subunits show great homologies in the region of the catalytic domain. The enzymes presumably contain one heme per heterodimer, which is bound via β<sub>1</sub>-Cys-78 and/or β<sub>1</sub>-His-105 and is part of the regulatory center.<!-- EPO <DP n="3"> --></p><p id="p0003" num="0003">Under pathologic conditions, the formation of guanylate-cyclase-activating factors can be reduced, or their degradation may be promoted owing to the increased occurrence of free radicals. The resulting reduced activation of the sGC leads, via a weakening of the respective cGMP-mediated cellular response, for example to an increase of the blood pressure, to platelet activation or to increased cell proliferation and cell adhesion. As a consequence, formation of endothelial dysfunction, atherosclerosis, hypertension, stable or unstable angina pectoris, thromboses, myocardial infarction, strokes or erectile dysfunction results. Pharmacological stimulation of sGC offers a possibility to normalize cGMP production and therefore makes possible the treatment and/or prevention of such disorders.</p><p id="p0004" num="0004">For the pharmacological stimulation of the sGC, use has hitherto almost exclusively been made of compounds whose activity is based on an intermediate NO release, for example organic nitrates. The drawback of this treatment is the development of tolerance and a reduction of activity, and the higher dosage which is required because of this.</p><p id="p0005" num="0005">Various sGC stimulators which do not act via NO release were described by Vesely in a series of publications. However, the compounds, most of which are hormones, plant hormones, vitamins or natural compounds such as, for example, lizard poisons predominantly only have weak effects on the cGMP formation in cell lysates (<nplcit id="ncit0001" npl-type="s"><text>D. L. Vesely, Eur. J. Clin. Invest. 15 (1985) 258</text></nplcit>; <nplcit id="ncit0002" npl-type="s"><text>D. L. Vesely, Biochem. Biophys. Res. Comm. 88 (1979) 1244</text></nplcit>). A stimulation of heme-free guanylate cyclase by protoporphyrin IX was demonstrated by <nplcit id="ncit0003" npl-type="s"><text>Ignarro et al. (Adv. Pharmacol. 26 (1994) 35</text></nplcit>). <nplcit id="ncit0004" npl-type="s"><text>Pettibone et al. (Eur. J. Pharmacol. 116 (1985) 307</text></nplcit>) described an antihypertensive action of diphenyliodonium hexafluorophosphate and attributed this to a stimulation of sGC. According to <nplcit id="ncit0005" npl-type="s"><text>Yu et al. (Brit. J. Pharmacol. 114 (1995) 1587</text></nplcit>), isoliquiritigenin, which has a relaxing action on isolated rat aortas, also activates sGC. <nplcit id="ncit0006" npl-type="s"><text>Ko et al. (Blood 84 (1994) 4226</text></nplcit>), <nplcit id="ncit0007" npl-type="s"><text>Yu et al. (Biochem. J. 306 (1995) 787</text></nplcit>) and <nplcit id="ncit0008" npl-type="s"><text>Wu et al. (Brit. J. Pharmacol. 116 (1995) 1973</text></nplcit>) demonstrated a sGC-stimulating activity of 1-benzyl-3-(5-hydroxymethyl-2-furyl)indazole and demonstrated an<!-- EPO <DP n="4"> --> antiproliferative and thrombocyte-inhibiting action. Pyrazoles and fused pyrazoles which exhibit a sGC-stimulating activity are described in <patcit id="pcit0001" dnum="EP908456A"><text>EP-A-908456</text></patcit> and <patcit id="pcit0002" dnum="DE19744027A"><text>DE-A-19744027</text></patcit></p><p id="p0006" num="0006">A series of 2-sulfonylaminobenzoic acid N-arylamides the N-aryl group of which carries a thio substituent have been mentioned in the literature. These compounds in which the N-aryl group generally carries as further substituents groups which are readily oxidizable such as, for example, two hydroxy groups being in para position with respect to one another and which in this case can be regarded as hydroquinone derivatives, are auxiliaries for the preparation of photographic materials (see, for example, <nplcit id="ncit0009" npl-type="s"><text>Chemical Abstracts 119, 105757</text></nplcit>; <nplcit id="ncit0010" npl-type="s"><text>120, 41858</text></nplcit>; <nplcit id="ncit0011" npl-type="s"><text>123, 70224</text></nplcit> or<nplcit id="ncit0012" npl-type="s"><text> 126, 257007</text></nplcit>). If isolated structural elements are considered then the N-aryl group in these known compounds corresponds to the group R<sup>1</sup>-S(O)<sub>n</sub>-A<sup>1</sup> in formula I in case A<sup>1</sup> denotes a 1,4-phenylene residue which in positions 2 and 5 carries hydroxy groups (or oxy substituents), and the number n is 0. British patent publication <patcit id="pcit0003" dnum="GB876526A"><text>876526</text></patcit> (Chemical Abstracts 56, 15432e) discloses 3,5-dichloro-2-methylsulfonylaminobenzoic acid N-(5-chloro-2-(4-chlorophenylmercapto)-phenyl)-amide which can be used for the protection of wool against moths. Compounds covered by <patcit id="pcit0004" dnum="GB876526A"><text>GB-A-876526</text></patcit> correspond to compounds of the formula I if simultaneously the ring A<sup>1</sup> which comprises the carbon atoms which carry the groups C(=X)-NH- and NH-SO<sub>2</sub>R<sup>2</sup>, together with the residues R<sup>3</sup>, is a benzene ring which carries one to four halogen atoms from the series chlorine and bromine, R<sup>2</sup> is (C<sub>1</sub>-C<sub>4</sub>)-alkyl, X is oxygen and the group R<sup>1</sup>-S(O)<sub>n</sub>-A<sup>1</sup>- is a phenylmercaptophenyl- residue (= phenylthiophenyl-) which is substituted by halogen and/or trifluoromethyl and which can also be substituted by methyl or (C<sub>1</sub>-C<sub>4</sub>)-alkoxy, and the total number of halogen atoms and trifluoromethyl groups is greater than two. Pharmacological activities of these known 2-sulfonylaminobenzoic acid N-arylamides are not disclosed.</p><p id="p0007" num="0007">Surprisingly, it has now been found that the compounds of the present invention effect a strong activation of guanylate cyclase and are therefore suitable for the therapy and prophylaxis of disorders which are associated with a low cGMP level.<!-- EPO <DP n="5"> --></p><p id="p0008" num="0008">Thus, the present invention relates to compounds of the formula I,
<chemistry id="chem0002" num="0002"><img id="ib0002" file="imgb0002.tif" wi="55" he="65" img-content="chem" img-format="tif"/></chemistry>
wherein<br/>
A<sup>1</sup> is a divalent heteroarylene residue which can be unsubstituted or substituted by one or more identical or different substituents from the series halogen, (C<sub>1</sub>-C<sub>4</sub>)-alkyl, CF<sub>3</sub>, -O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl and -CN;<br/>
the ring A<sup>2</sup>, which comprises the two carbon atoms which carry the groups R<sup>2</sup>-SO<sub>2</sub>-NH and C(=X)-NH-, is a benzene ring, a pyridine ring, a thiophene ring or a pyrazole ring;<br/>
R<sup>1</sup> is (C<sub>1</sub>-C<sub>7</sub>)-alkyl; or is phenyl which can be substituted by one or more identical or different substituents from the series halogen, (C<sub>1</sub>-C<sub>4</sub>)-alkyl, phenyl, CF<sub>3</sub>, NO<sub>2</sub>, -O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, (C<sub>1</sub>-C<sub>2</sub>)-alkylenedioxy, NH<sub>2</sub>, -NH-CO-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, -CN, -CO-NH<sub>2</sub>, -CO-OH and -CO-O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl; or, if the number n in the group R<sup>1</sup>-S(O)<sub>n</sub>- is 2, also is NR<sup>5</sup>R<sup>6</sup>;<br/>
R<sup>2</sup> is aryl;<br/>
<!-- EPO <DP n="6"> -->R<sup>3</sup> denotes one or more identical or different residues from the series hydrogen, halogen, CF<sub>3</sub>, -O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, -CN and (C<sub>1</sub>-C<sub>4</sub>)-alkyl;<br/>
R<sup>5</sup> and R<sup>6</sup>, independently of one another, are hydrogen, or (C<sub>1</sub>-C<sub>9</sub>)-alkyl which can be unsubstituted or substituted by aryl, or (C<sub>2</sub>-C<sub>9</sub>)-alkenyl, or (C<sub>3</sub>-C<sub>9</sub>)-cycloalkyl, or (C<sub>1</sub>-C<sub>4</sub>)-alkyl-O-(C<sub>1</sub>-C<sub>3</sub>)-alkyl-, or together with the nitrogen atom carrying R<sup>5</sup> and R<sup>6</sup> form a 5-membered to 7-membered, saturated or partially unsaturated heterocycle which, in addition to the nitrogen atom carrying the groups R<sup>5</sup> and R<sup>6</sup>, can contain one further ring heteroatom from the series N, O and S, and which can be substituted by one or more identical or different residues from the series (C<sub>1</sub>-C<sub>3</sub>)-alkyl, hydroxy-(C<sub>1</sub>-C<sub>3</sub>)-alkyl-, aryl, carbamoyl, hydroxy and oxo;<br/>
aryl is phenyl or heteroaryl which can all be substituted by one or more identical or different substituents from the series halogen, (C<sub>1</sub>-C<sub>4</sub>)-alkyl, phenyl, CF<sub>3</sub>, NO<sub>2</sub>, -O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, (C<sub>1</sub>-C<sub>2</sub>)-alkylenedioxy, NH<sub>2</sub>, -NH-CO-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, -CN, -CO-NH<sub>2</sub>, -CO-OH and -CO-O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl;<br/>
heteroaryl and heteroarylene are a residue of a monocyclic 5-membered or 6-membered aromatic heterocycle which contains one or two identical or different ring heteroatoms from the series N, O and S;<br/>
n is 0 or 2;<br/>
X is oxygen;<br/>
in all its stereoisomeric forms and mixtures thereof in all ratios, and its physiologically acceptable salts;<br/>
where only up to two nitro groups can be present in a compound of the formula I.<!-- EPO <DP n="7"> --></p><p id="p0009" num="0009">If groups or substituents can occur several times in the compounds of formula I such as, for example R<sup>3</sup>, R<sup>5</sup>, aryl, alkyl or the number n, they can all independently of one another have the meanings indicated and can in each case be identical or different.</p><p id="p0010" num="0010">Alkyl residues can be straight-chain or branched. This also applies when they are part of other groups, for example in alkoxy groups, alkoxycarbonyl groups or amino groups, or when they are substituted. Examples of alkyl groups are methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, the n-isomers of these residues, isopropyl, isobutyl, isopentyl, sec-butyl, tert-butyl, neopentyl, 3,3-dimethylbutyl.</p><p id="p0011" num="0011">Examples of alkenyl residues, i. e. unsaturated alkyl residues which contain at least two carbon atoms and which contain one or more double bonds, are the vinyl residue, the 1-propenyl residue, the 2-propenyl residue (allyl residue), the 2-butenyl residue, the 2-methyl-2-propenyl residue, or the 3-methyl-2-butenyl residue.</p><p id="p0012" num="0012">Examples of cycloalkyl residues, i. e. alkyl residues in which by an internal ring closure within the alkyl group a cyclic system is formed and which contain at least three carbon atoms, are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl which can all also be substituted by one or more identical or different (C<sub>1</sub>-C<sub>4</sub>)-alkyl residues, in particular by methyl. Examples of such substituted cycloalkyl residues are 4-methylcyclohexyl, 4-tert-butylcyclohexyl or 2,3-dimethylcyclopentyl.</p><p id="p0013" num="0013">Examples of arylalkyl- residues, i. e. alkyl residues which are substituted by one or more, for example one, two, three or four, identical or different aryl residues, such as, for example, aryl-(C<sub>1</sub>-C<sub>4</sub>)-alkyl-, are benzyl residues, phenylethyl residues or indanyl residues. In substituted alkyl residues, for example arylalkyl-, hydroxyalkyl- such as -(C<sub>1</sub>-C<sub>3</sub>)-alkyl-OH or alkoxyalkyl- such as -(C<sub>1</sub>-C<sub>3</sub>)-alkyl-O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, the substituents can be present in any desired position.<!-- EPO <DP n="8"> --></p><p id="p0014" num="0014">Unless stated otherwise, phenyl residues and heterocyclic residues, for example heteroaryl residues, can be unsubstituted or can carry one or more, for example one, two, three or four, identical or different substituents which can be in any desired positions. Unless stated otherwise, in these residues for example those substituents can be present which are indicated as substituents of an aryl group. A preferred series of substituents that can be present in the residue aryl is formed by the substituents halogen, (C<sub>1</sub>-C<sub>4</sub>)-alkyl, phenyl, CF<sub>3</sub>, NO<sub>2</sub>, -O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, (C<sub>1</sub>-C<sub>2</sub>)-alkylenedioxy, NH<sub>2</sub>, -NH-CO-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, -CN, -CO-NH<sub>2</sub>, -CO-OH, -CO-O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl. If in compounds of the formula I nitro groups are present as substituents, in total only up to two nitro groups can be present in the molecules. If phenyl residues are present as<!-- EPO <DP n="9"> --> substituents in, for example, aryl residues like phenyl residues and/or in heterocyclic residues then in these substituents the benzene ring can also be unsubstituted or substituted by one or more, for example one, two, three or four, identical or different residues, for example by residues from the series (C<sub>1</sub>-C<sub>4</sub>)-alkyl, halogen, (C<sub>1</sub>-C<sub>4</sub>)-alkoxy, trifluoromethyl, cyano, hydroxycarbonyl, ((C<sub>1</sub>-C<sub>4</sub>)-alkoxy)carbonyl, aminocarbonyl, nitro, amino and ((C<sub>1</sub>-C<sub>4</sub>)-alkyl)carbonylamino.</p><p id="p0015" num="0015">In monosubstituted phenyl residues the substituent can be in the 2-position, the 3-position or the 4-position, in disubstituted phenyl residues the substituents can be in 2,3-position, 2,4-position, 2,5-position, 2,6-position, 3,4-position or 3,5-position. In trisubstituted phenyl residues the substituents can be in 2,3,4-position, 2,3,5-position, 2,3,6-position, 2,4,5-position, 2,4,6-position or 3,4,5-position. Tolyl (= methylphenyl) can be 2-tolyl, 3-tolyl or 4-tolyl.</p><p id="p0016" num="0016">The above explanations as well as the following explanations relating to monovalent residues correspondingly apply to the divalent residues heteroarylene. The free bonds via which the divalent residues are attached to the adjacent groups can be present on any ring carbon atoms. In the case of 5-membered ring aromatics containing one heteroatom such as, for example, thiophene or furan, the two free bonds can be in 2,3-position, 2,4-position, 2,5-position or 3,4-position. A divalent<!-- EPO <DP n="10"> --> residue derived from pyridine can be a 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5-pyridinediyl residue. In the case of unsymmetrical divalent residues the present invention includes all positional isomers, i. e., in the case of a 2,3-pyridinediyl residue, for example, it includes the compound in which the one adjacent group is present in the 2-position and the other adjacent group is present in the 3-position as well as the compound in which the one adjacent group is present in the 3-position and the other adjacent group is present in the 2-position.</p><p id="p0017" num="0017">Heteroaryl residues, heteroarylene residues, heterocycles representing the ring A<sup>2</sup> and rings which are formed by two groups bonded to a nitrogen atom together with this nitrogen atom are preferably derived from heterocycles which contain one or two, identical or different heteroatoms. Unless stated otherwise, the heterocycles can be monocyclic or bicyclic. The rings preferably are 5-membered rings, 6-membered ring or 7-membered ring. Examples of monocyclic and bicyclic heterocyclic systems from which residues occuring in the compounds of the formula I can be derived, are pyrrole, furan, thiophene, imidazole, pyrazole, 1,3-dioxole, 1,3-oxazole (= oxazole), 1,2-oxazole (= isoxazole), 1,3-thiazole (= thiazole), 1,2-thiazole (= isothiazole), pyridine, pyridazine, pyrimidine, pyrazine, pyran, thiopyran, 1,4-dioxine, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine, 1,2-thiazine, 1,3-thiazine, 1,4-thiazine, azepine, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, 1,3-oxazepine, 1,3-thiazepine, indole, benzothiophene, benzofuran, benzothiazole, benzimidazole, quinoline, isoquinoline, cinnoline, quinazoline, quinoxaline, phthalazine, thienothiophenes, 1,8-naphthyridine and other naphthyridines, each of them in saturated form (perhydro form) or in partially unsaturated form (for example in the dihydro form or the tetrahydro form) or in maximally unsaturated form, insofar as the respective forms are known and stable. Thus, the heterocycles which are suitable also include, for<!-- EPO <DP n="11"> --></p><p id="p0018" num="0018">example, the saturated heterocycles pyrrolidine, piperidine, piperazine, morpholine and thiomorpholine. The degree of saturation of heterocyclic groups is indicated in their individual definitions. Unsaturated heterocycles can contain, for example, one, two or three double bonds within the ring system. 5-membered rings and 6-membered rings can in particular also be aromatic.</p><p id="p0019" num="0019">The residues derived from these heterocycles can be attached via any suitable carbon atom. Nitrogen heterocycles which can carry a hydrogen atom or a substituent on a ring nitrogen atom, for example pyrrole, imidazole, pyrrolidine, morpholine, piperazine, can also be attached via a ring nitrogen atom, in particular if the heterocyclic residue in question is bonded to a carbon atom. For example, a thienyl residue can be present as 2-thienyl residue or 3-thienyl residue, a furyl residue as 2-furyl residue or 3-furyl residue, a pyridyl residue as 2-pyridyl residue, 3-pyridyl residue or 4-pyridyl residue, a piperidinyl residue as 1-piperidinyl residue (= piperidino residue), 2-piperidinyl residue, 3-piperidinyl residue or 4-piperidinyl residue, a (thio)morpholinyl residue as 2-(thio)morpholinyl residue, 3-(thio)morpholinyl residue or 4-(thio)morpholinyl residue (= thiomorpholino residue). A residue derived from 1,3-thiazole or imidazole which is attached via a carbon atom can be attached via the 2-position, the 4-position or the 5-position.</p><p id="p0020" num="0020">Unless stated otherwise the heterocyclic groups can be unsubstituted or can carry one or more, for example one, two three or four, identical or different substituents. Substituents in heterocycles can be present in any desired positions, for example in a 2-thienyl residue or 2-furyl residue in the 3-position and/or in the 4-position and/or in the 5-position, in a 3-thienyl residue or 3-furyl residue in the 2-position and/or in the 4-position and/or in the 5-position, in a 2-pyridyl residue in the 3-position and/or in the 4-position and/or in the 5-position and/or in the 6-position, in a 3-pyridyl residue in the 2-position and/or in the 4-position and/or in the 5-position and/or in the 6-position, in a 4-pyridyl residue in the 2-position and/or in the 3-position and/or in the 5-position and/or in the 6-position. Unless stated otherwise, for example those substituents can be present as substituents in heterocyclic groups which are<!-- EPO <DP n="12"> --> indicated in the definition of the group aryl, and in the case of saturated and partially unsaturated heterocycles as further substituents also the oxo group can be present. Substituents on a heterocycle as well as substituents on a carbocycle can also form a ring, i. e. to a ring system further rings can be condensed (or anellated) so that, for example, also cyclopenta-condensed, cyclohexa-condensed or benzo-condensed rings can be present. Suitable substituents on a substitutable ring nitrogen atom of a heterocycle are in particular, for example, unsubstituted (C<sub>1</sub>-C<sub>4</sub>)-alkyl residues, or aryl residues. Suitable nitrogen heterocycles can also be present as N-oxides or as quarternary salts containing a counterion which is derived from a physiologically acceptable acid. Pyridyl residues, for example, can be present as pyridine-N-oxides.</p><p id="p0021" num="0021">Halogen is fluorine, chlorine, bromine oder iodine, preferably fluorine or chlorine.</p><p id="p0022" num="0022">Without limiting the present invention, in the formulae Ia, Ie, If, Ig and Ih examples of groups of compounds of the invention are shown in which A<sup>2</sup> in the formula I has specific denotations. A<sup>1</sup>, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, X and n in the formulae Ia, Ie, If, Ig and Ih are defined as above for the formula I.
<chemistry id="chem0003" num="0003"><img id="ib0003" file="imgb0003.tif" wi="69" he="59" img-content="chem" img-format="tif"/></chemistry><!-- EPO <DP n="13"> -->
<chemistry id="chem0004" num="0004"><img id="ib0004" file="imgb0004.tif" wi="146" he="62" img-content="chem" img-format="tif"/></chemistry>
<chemistry id="chem0005" num="0005"><img id="ib0005" file="imgb0005.tif" wi="144" he="75" img-content="chem" img-format="tif"/></chemistry><!-- EPO <DP n="14"> --></p><p id="p0023" num="0023">On the benzene ring depicted in formula la which carries the groups C(=X)-NH- and -NHSO<sub>2</sub>R<sup>2</sup> four positions are present which can carry a residue R<sup>3</sup>. The compounds of formula la can thus carry four residues R<sup>3</sup> which according to the definition of R<sup>3</sup> can all independently of one another be hydrogen or can have a meaning different from hydrogen, i. e., in the compounds of formula la the benzene ring depicted in formula Ia can be unsubstituted or can carry one, two, three or four identical or different substituents from the series halogen, CF<sub>3</sub>, -O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, -CN and (C<sub>1</sub>-C<sub>4</sub>)-alkyl. These explanations accordingly apply to the compounds of formulae le to Ih.<!-- EPO <DP n="15"> --></p><p id="p0024" num="0024">The present invention includes all stereoisomeric forms of the compounds of the formula I. Centers of asymmetry that are present in the compounds of formula I can all independently of one another have S configuration or R configuration. The invention includes all possible enantiomers and diastereomers and mixtures of two or more stereoisomers, for example mixtures of enantiomers and/or diastereomers, in all ratios. Thus, enantiomers are a subject of the invention in enantiomerically pure form, both as levorotatory and as dextrorotatory antipodes, in the form of racemates and in the form of mixtures of the two enantiomers in all ratios. In the case of a cis/trans isomerism the invention includes both the cis form and the trans form as well as mixtures of these forms in all ratios. The preparation of individual stereoisomers can be carried out, if desired, by separation of a mixture by customary methods, for example by chromatography or crystallization, by the use of stereochemically uniform starting materials for the synthesis or by stereoselective synthesis. Optionally a derivatization can be carried out before a separation of stereoisomers. The separation of a mixture of stereoisomers can be carried out at the stage of the compounds of the formula I or at the stage of an intermediate during the synthesis. The present invention also includes all tautomeric forms of the compounds of formula I.</p><p id="p0025" num="0025">If the compounds of the formula I contain one or more acidic or basic groups the invention also includes the corresponding physiologically or toxicologically acceptable salts, in particular the pharmaceutically utilizable salts. Thus, the compounds of the formula I which contain acidic groups can be present on these groups and can be used according to the invention, for example, as alkali metal<!-- EPO <DP n="16"> --> salts, alkaline earth metal salts or as ammonium salts. Examples of such salts are sodium salts, potassium salts, calcium salts, magnesium salts or salts with ammonia or organic amines such as, for example, ethylamine, ethanolamine, triethanolamine or amino acids. Compounds of the formula I which contain one or more basic groups, i.e. groups which can be protonated, can be present and can be used according to the invention in the form of their acid addition salts with inorganic or organic acids, for example as salts with hydrogen chloride, hydrogen bromide, phosphoric acid, sulfuric acid, nitric acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenedisulfonic acids, oxalic acid, acetic acid, tartaric acid, lactic acid, salicylic acid, benzoic acid, formic acid, propionic acid, pivalic acid, diethylacetic acid, malonic acid, succinic acid, pimelic acid, fumaric acid, maleic acid, malic acid, sulfaminic acid, phenylpropionic acid, gluconic acid, ascorbic acid, isonicotinic acid, citric acid, adipic acid. If the compounds of the formula I simultaneously contain acidic and basic groups in the molecule the invention also includes, in addition to the salt forms mentioned, inner salts or betaines (zwitterions). Salts can be obtained from the compounds of the formula I by customary methods which are known to the person skilled in the art, for example by combination with an organic or inorganic acid or base in a solvent or dispersant, or by anion exchange or cation exchange from other salts. The present invention also includes all salts of the compounds of he formula I which, owing to low physiological compatibility, are not directly suitable for use in pharmaceuticals but which can be used, for example, as intermediates for chemical reactions or for the preparation of physiologically acceptable salts.</p><p id="p0026" num="0026">The present invention furthermore includes all solvates of compounds of the formula I, for example hydrates or adducts with alcohols, and also derivatives of the compounds of the formula I such as, for example esters, amides, prodrugs and active metabolites.</p><p id="p0027" num="0027">The 5-membered or 6-membered heteroarylene residue representing A<sup>1</sup> can be unsubstituted or can be substituted as indicated. If the group A<sup>1</sup> is substituted, i. e. if it carries one or more further substituents in addition to the group R<sup>1</sup>-S(O)<sub>n</sub>, it is<!-- EPO <DP n="17"> --> preferably substituted by one or two identical or different of the substituents indicated above. The group R<sup>1</sup>-S(O)<sub>n</sub> is preferably attached to a carbon atom in A<sup>1</sup> which is not directly adjacent to the carbon atom which carries the group C(=X)-NH.</p><p id="p0028" num="0028">The ring A<sup>2</sup> which comprises the two carbon atoms which carry the groups R<sup>2</sup>-SO<sub>2</sub>-NH and C(=X)-NH- preferably is a benzene ring or a thiophene ring, particularly preferably a benzene ring, where all these rings can be unsubstituted or substituted by one ore more residues R<sup>3</sup> which are different from hydrogen.</p><p id="p0029" num="0029">R<sup>1</sup> preferably is NR<sup>5</sup>R<sup>6</sup> or phenyl, particularly preferably NR<sup>5</sup>R<sup>6</sup>, where all these residues can be unsubstituted or substituted as indicated and where, as stated above, R<sup>1</sup> can be NR<sup>5</sup>R<sup>6</sup> if the number n in the group R<sup>1</sup>-S(O)<sub>n</sub>- is 2.</p><p id="p0030" num="0030">R<sup>2</sup> is aryl, i. e. phenyl or a residue of a monocyclic 5-membered or 6-membered aromatic heterocycle, which contains one or two identical or different heteroatoms from the series N, O and S, such as, for example, phenyl, thienyl, pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, pyridyl, in particular phenyl or 2-thienyl, where all these residues can be unsubstituted or substituted as indicated. Preferably an aryl residue representing R<sup>2</sup> is substituted. If an aryl residue representing R<sup>2</sup> is substituted it is preferably substituted by one, two or three, in particular by one or two, identical or different substituents. Substituents in an aryl residue representing R<sup>2</sup> preferably are substituents from the series halogen, CF<sub>3</sub>,<!-- EPO <DP n="18"> --></p><p id="p0031" num="0031">NO<sub>2</sub>, -CN, (C<sub>1</sub>-C<sub>4</sub>)-alkyl and -O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, more preferably substituents from the series F, Cl, Br, CF<sub>3</sub>, NO<sub>2</sub>, -CN, CH<sub>3</sub> and -OCH<sub>3</sub>. Especially preferably a substituted aryl residue representing R<sup>2</sup> is substituted by Cl, for example by one or two, in particular one, chlorine atoms.</p><p id="p0032" num="0032">The rings representing A<sup>2</sup> can be unsubstituted or substituted as indicated. When they are unsubstituted they only carry residues R<sup>3</sup> which are hydrogen. When they are substituted they carrry one or more residues R<sup>3</sup> which are different from hydrogen. Those substituent positions which do not carry a residue R<sup>3</sup> which is different from hydrogen, carry hydrogen atoms. If the ring A<sup>2</sup> carries one or more residues R<sup>3</sup> which are different from hydrogen it preferably carries one or two such residues R<sup>3</sup>, in particular one such residue R<sup>3</sup>. Residues R<sup>3</sup> which are different from hydrogen are preferably located in positions of the ring A<sup>2</sup> which are not directly adjacent to the groups C(=X)-NH and R<sup>2</sup>-SO<sub>2</sub>-NH. In particular if A<sup>2</sup> is a benzene ring, residues R<sup>3</sup> which are different from hydrogen preferably are (C<sub>1</sub>-C<sub>3</sub>)-alkyl, halogen, (C<sub>1</sub>-C<sub>3</sub>)-alkoxy or CF<sub>3</sub>, more preferably methyl, chlorine or methoxy. In particular if A<sup>2</sup> is a benzene ring, it is very particularly preferred if the ring carries one chlorine atom or two methoxy groups as substituents, i. e., if one residue R<sup>3</sup> is present which is chlorine or if two residues R<sup>3</sup> are present which are methoxy, and the other positions on the benzene ring carry hydrogen atoms. If A<sup>2</sup> is a benzene ring, residues R<sup>3</sup> which are different from hydrogen are preferably located in positions 4 and/or 5 (with respect to the group C(=X)-NH in the 1-position and the group R<sup>2</sup>-SO<sub>2</sub>-NH in the 2-position).</p><p id="p0033" num="0033">With respect to R<sup>5</sup> and R<sup>6</sup> it is preferred if R<sup>5</sup> and R<sup>6</sup> together with the<!-- EPO <DP n="19"> --> nitrogen atom carrying these residues form a 5-membered, 6-membered or 7-membered heterocycle which in addition to the nitrogen atom carrying the groups R<sup>5</sup> and R<sup>6</sup> can contain one further ring heteroatom from the series N, O and S and which can be substituted by one or more, for example one, two, three or four, identical or different residues from the series (C<sub>1</sub>-C<sub>3</sub>)-alkyl, hydroxy-(C<sub>1</sub>-C<sub>3</sub>)-alkyl-, 5-membered or 6-membered aryl, carbamoyl, hydroxy and oxo, in particular (C<sub>1</sub>-C<sub>3</sub>)-alkyl such as, for example, methyl. Preferably a heterocycle which is formed from the groups R<sup>5</sup> and R<sup>6</sup> together with the nitrogen atom carrying these residues is saturated.</p><p id="p0034" num="0034">Especially preferably a heterocycle which is formed by R<sup>5</sup> and R<sup>6</sup> together with the nitrogen atom carrying these residues, is derived from morpholine, thiomorpholine, 1,1-dioxo-thiomorpholine, 1-oxo-thiomorpholine, from dialkylmorpholines such as dimethylmorpholines, from 2,6-dimethylmorpholine, cis-2,6-dimethylmorpholine, 3,5-dimethylmorpholine, cis-3,5-dimethylmorpholine, 1-(pyrimidin-2-yl)-piperazine, piperidine-4-carboxamide, 1-(2-hydroxyethyl)-piperazine, 1-methylpiperazine, 1-ethylpiperazine, from 1-arylpiperazines, from ethyl piperazine-1-carboxylate, piperidine, 2-methylpiperidine, 2,6-dimethylpiperidine, cis-2,6-dimethylpiperidine, 3,5-dimethylpiperidine, cis-3,5-dimethylpiperidine, 4-hydroxypiperidine, from 4-oxopiperidine or a ketal thereof like 1,4-dioxa-8-aza-spiro[4.5]decan, from tetrahydropyridine, tetrahydropyrimidine, 1-methylhomopiperazine, thiazolidine, pyrroline, pyrrolidine, 3-hydroxypyrrolidine, 1,2,3,4-tetrahydroisoquinoline or 2,3-dihydro-1H-isoindole, where these rings are attached via the ring nitrogen atom or,<!-- EPO <DP n="20"> --> in the case of piperazine derivatives, via the unsubstituted ring nitrogen atom. More especially preferably a heterocycle which is formed by R<sup>5</sup> and R<sup>6</sup> together with the nitrogen atom carrying these residues, is derived from morpholine, thiomorpholine, 1,1-dioxo-thiomorpholine, 1-oxo-thiomorpholine, 2,6-dimethylmorpholine, cis-2,6-dimethylmorpholine, 3,5-dimethylmorpholine, cis-3,5-dimethylmorpholine, 1-(pyrimidin-2-yl)-piperazine, piperidine-4-carboxamide, 1,2,3,4-tetrahydroisoquinoline or 2,3-dihydro-1H-isoindole, moreover preferably from morpholine, 2,6-dimethylmorpholine or cis-2,6-dimethylmorpholine, in particular from morpholine or cis-2,6-dimethylmorpholine, where these rings are attached via the ring nitrogen atom or, in the case of the piperazine derivative, via the unsubstituted ring nitrogen atom.</p><p id="p0035" num="0035">Aryl preferably is phenyl or heteroaryl, in particular phenyl or 5-membered or 6-membered heteroaryl. Unless stated otherwise, preferred substituents on aryl residues are halogen, CF<sub>3</sub>, (C<sub>1</sub>-C<sub>3</sub>)-alkyl, cyano, nitro and (C<sub>1</sub>-C<sub>3</sub>)-alkyloxy, more preferred substituents are CF<sub>3</sub>, chlorine, methyl and methoxy.</p><p id="p0036" num="0036">Heteroaryl and heteroarylene preferably are a residue of a monocyclic 5-membered or 6-membered aromatic heterocycle, in particular a residue derived from the heteroaromatics thiophene, pyrazole, thiazole, oxazole, isoxazole, pyridine, pyrimidine, pyridazine.<!-- EPO <DP n="21"> --></p><p id="p0037" num="0037">The number n in the group R<sup>1</sup>-S(O)<sub>n</sub> preferably is 2.</p><p id="p0038" num="0038">Preferred compounds of the formula I are those compounds in which one or more of the residues contained therein have preferred meanings, all combinations of preferred substituent definitions being a subject of the present invention. Also with respect to all preferred compounds of the formula I the present invention includes all stereoisomeric forms and mixtures thereof in all ratios, and their physiologically acceptable salts. Groups of preferred compounds are also formed, for example, by the compounds of the formulae Ia, Ie, If, Ig and Ih in which one or more residues have preferred meanings, in all their stereoisomeric forms and mixtures thereof in all ratios, and their physiologically acceptable salts.</p><p id="p0039" num="0039">A group of particularly preferred compounds is formed, for example, by compounds of the formula I in which<br/>
A<sup>1</sup> is a divalent heteroarylene residue which can be unsubstituted or substituted by one or more identical or different substituents from the series halogen, (C<sub>1</sub>-C<sub>4</sub>)-alkyl, CF<sub>3</sub>, -O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl and -CN;<br/>
the ring A<sup>2</sup>, which comprises the two carbon atoms which carry the groups R<sup>2</sup>-SO<sub>2</sub>-NH and C(=X)-NH-, is a benzene ring;<br/>
R<sup>1</sup> is NR<sup>5</sup>R<sup>6</sup>;<br/>
R<sup>2</sup> is aryl;<br/>
R<sup>3</sup> denotes one or more identical or different residues from the series hydrogen, (C<sub>1</sub>-C<sub>3</sub>)-alkyl, halogen, (C<sub>1</sub>-C<sub>3</sub>)-alkoxy and CF<sub>3</sub>;<br/>
R<sup>5</sup> and R<sup>6</sup> together with the nitrogen atom carrying R<sup>5</sup> and R<sup>6</sup> form a 5-membered, 6-membered or 7-membered saturated heterocycle which, in addition to the nitrogen atom carrying the groups R<sup>5</sup> and R<sup>6</sup>, can contain one further ring heteroatom from the<!-- EPO <DP n="22"> --> series N, O and S, and which can be substituted by one or more identical or different residues from the series (C<sub>1</sub>-C<sub>3</sub>)-alkyl, hydroxy-(C<sub>1</sub>-C<sub>3</sub>)-alkyl-, aryl, carbamoyl, hydroxy and oxo;<br/>
aryl is phenyl or heteroaryl which can all be substituted by one or more identical or different substituents from the series halogen, (C<sub>1</sub>-C<sub>4</sub>)-alkyl, phenyl, CF<sub>3</sub>, NO<sub>2</sub>, -O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, (C<sub>1</sub>-C<sub>2</sub>)-alkylenedioxy, NH<sub>2</sub>, -NH-CO-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, -CN, -CO-NH<sub>2</sub>, -CO-OH and -CO-O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl;<br/>
heteroaryl and heteroarylene are a residue of a monocyclic 5-membered or 6-membered aromatic heterocycle which contains one or two identical or different ring heteroatoms from the series N, O and S;<br/>
n is 2;<br/>
X is oxygen;<br/>
in all their stereoisomeric forms and mixtures thereof in all ratios, and their physiologically acceptable salts.<!-- EPO <DP n="23"> --></p><p id="p0040" num="0040">The presents invention also relates to processes for the preparation of the compounds of the formula I which are described in the following and by which the compounds of the invention are obtainable. According to Scheme 1 compounds of the invention can be obtained, for example, by first reacting an aminocarboxylic acid of the formula II with a sulfonyl chloride of the formula R<sup>2</sup>-SO<sub>2</sub>-Cl or a sulfonic acid anhydride in the presence of a base in a solvent like water, pyridine or an ether. Suitable bases are inorganic bases like sodium carbonate or organic bases like, for example, pyridine or triethylamine. The sulfonylaminocarboxylic acid of the formula III that is obtained can then be activated, for example by reaction with a chlorinating<!-- EPO <DP n="24"> --> agent like phosphorus pentachloride, phosphorus oxychloride or thionyl chloride in an inert solvent, to give an acid chloride of the formula IV which is then reacted with an arylamine. The activation of the carboxylic acid group in the compounds of the formula III can, however, also be carried our in a different manner, for example by one of the numerous methods for the formation of amide bonds in peptide chemistry which are well-known to the skilled person, for example by conversion into a mixed anhydride or an activated ester or by using a carbodiimide like dicyclohexylcarbodimide.</p><p id="p0041" num="0041">The reaction of the activated sulfonylaminocarboxylic acid with an arylamine is favorably carried out in an inert solvent such as, for example, pyridine, tetrahydrofuran or toluene in the absence or in the presence of an inert auxiliary base like, for example, a tertiary amine or pyridine. If the arylamine that is employed in the reaction with the activated carboxylic acid already contains the desired substituent R<sup>1</sup>-S(O)<sub>n</sub> then the reaction directly provides the final compound of the formula I. Compounds of the formula I in which the number n in the group R<sup>1</sup>-S(O)<sub>n</sub> is 2 can also be obtained by reacting an activated carboxylic acid with a mercapto substituted arylamine of the formula R<sup>1</sup>-S-A<sup>1</sup>-NH<sub>2</sub> and then oxidizing the mercapto group in the compound of the formula V under standard conditions, for example with a peroxide like hydrogen peroxide or a peracid like 3-chloroperbenzoic acid or monoperoxyphthalic acid in a solvent like, for example, methylene chloride or acetone. The activated carboxylic acids can also first be reacted with arylamines of the formula A<sup>1</sup>-NH<sub>2</sub>. The resulting reaction product of the formula VI can then be chlorosulfonated under standard conditions and the chlorosulfonyl group can then be converted under standard conditions into the group R<sup>1</sup>-SO<sub>2</sub>, for example by reaction with suitable amines in substance or in a solvent like N-methylpyrrolidone, dimethylformamide, toluene or an ether, optionally in the presence of an auxiliary base. In a similar manner the activated carboxylic acids can be reacted with<!-- EPO <DP n="25"> -->
<chemistry id="chem0006" num="0006"><img id="ib0006" file="imgb0006.tif" wi="165" he="207" img-content="chem" img-format="tif"/></chemistry><!-- EPO <DP n="26"> -->
fluorosulfonylarylamines of the formula F-SO<sub>2</sub>-A<sup>1</sup>-NH<sub>2</sub> and the fluorosulfonyl intermediates of the formula VII that are obtained can be converted under standard conditions into the compounds of the formula I according to the invention.</p><p id="p0042" num="0042">The compounds of the formula I according to the invention can furthermore be obtained by reacting the activated sulfonylaminocarboxylic acids, for example the acid chlorides of the formula IV shown in Scheme 1, with a mercaptoarylamine of the formula H<sub>2</sub>N-A<sup>1</sup>-SH which is unsubstituted on the sulfur atom. In a nucleophilic substitution reaction the product of the formula VIII that is obtained can subsequently be alkylated or arylated on the sulfur atom with an alkyl halogenide or an aryl halogenide or another reactive compound under standard conditions and, if desired, be oxidized on the sulfur to give the sulfone as explained above with respect to the compounds of the formula V (see Scheme 2).
<chemistry id="chem0007" num="0007"><img id="ib0007" file="imgb0007.tif" wi="152" he="75" img-content="chem" img-format="tif"/></chemistry>
Compounds of the formula I can also be obtained, for example, by first activating a suitably substituted nitrocarboxylic acid of the formula IX, for example by converting it into the respective acid chloride of the formula X or by another procedure, and then reacting it with a substituted arylamine of the formula R<sup>1</sup>-S(O)<sub>n</sub>-A<sup>1</sup>-NH<sub>2</sub><!-- EPO <DP n="27"> -->
<chemistry id="chem0008" num="0008"><img id="ib0008" file="imgb0008.tif" wi="158" he="220" img-content="chem" img-format="tif"/></chemistry><!-- EPO <DP n="28"> -->
analogously to the procedures described above (see Scheme 3). Here, too, as arylamines fluorosulfonylarylamines of the formula F-SO<sub>2</sub>-A<sup>1</sup>-NH<sub>2</sub> can be employed, and in the N-(fluorosulfonylaryl)-carboxamides of the formula XI that are obtained the fluorosulfonyl group can be converted under standard conditions into a group R<sup>1</sup>-SO<sub>2</sub> according to the invention, for example with an amine of the formula HNR<sup>5</sup>R<sup>6</sup>.</p><p id="p0043" num="0043">Before subsequently in the nitro intermediates of the formula XII that are obtained the nitro group is reduced to an amino group use can be made of the activating effect of the nitro group onto the ring A<sup>2</sup> and a suitable residue R<sup>3</sup>, for example a halogen atom, can be replaced with a different residue R<sup>3</sup> by reaction with a nucleophil, for example an amine. The reduction of the nitro group to give an amino group can, for example, be carried out by catalytic hydrogenation in the presence of a noble metal catalyst or, preferably, in the presence of Raney nickel in a solvent like ethanol, glacial acetic acid or a ethanolic solution of hydrogen chloride, or it can be carried out by reduction with a base metal like zinc, tin or iron in the presence of an acid. The reduction can also be carried out, for example, with tin(II) chloride or by reaction with sodium dithionite, favorably in a mixture of methanol, tetrahydrofuran and water as solvent. The sulfonylation of the amino group in the reduction product of the formula XIII with an activated sulfonic acid derivative can be carried out analogously to the reactions described above, for example with a sulfonic acid chloride in pyridine, and finally gives the compound of the formula I.<!-- EPO <DP n="29"> --></p><p id="p0044" num="0044">All reactions for the synthesis of the compounds of the formula I are per se well-known to the skilled person and can be carried out under standard conditions according to or analogously to procedures described in the literature, for example in<!-- EPO <DP n="30"> --> <nplcit id="ncit0013" npl-type="b"><text>Houben-Weyl, Methoden der Organischen Chemie (Methods of Organic Chemistry), Thieme-Verlag, Stuttgart</text></nplcit>, or <nplcit id="ncit0014" npl-type="b"><text>Organic Reactions, John Wiley &amp; Sons, New York</text></nplcit>. Depending on the circumstances of the individual case, in order to avoid side reactions during the synthesis of a compound of the formula I it can be necessary or advantageous to temporarily block functional groups by introducing protective groups and to deprotect them in a later stage of the synthesis, or introduce functional groups in the form of precursor groups which in a later reaction step are converted into the desired functional groups. Such synthetic strategies and protective groups and precursor groups which are suitable in an individual case are known to the skilled person. If desired the compounds of the formula I can be purified by customary purification procedures, for example by recrystallization or chromatography. The starting compounds for the preparation of the compounds of the formula I are commercially available or can be prepared according to or analogously to literature procedures.</p><p id="p0045" num="0045">The compounds of the formula I according to the invention effect an increase of the cGMP concentration via the activation of the soluble guanylate cyclase (sGC), and they are therefore useful agents for the therapy and prophylaxis of disorders which are associated with a low or decreased cGMP level or which are caused thereby, or for whose therapy or prophylaxis an increase of the present cGMP level is desired. The activation of the sGC by the compounds of the formula I can be examined, for example, in the activity assay described below.</p><p id="p0046" num="0046">Disorders and pathological conditions which are associated with a low cGMP level or in which an increase of the cGMP level is desired and for whose therapy and prophylaxis it is possible to use compounds of the formula I are, for example, cardiovascular diseases, such as endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, stable and unstable angina pectoris, thromboses, restenoses, myocardial infarction, strokes, cardiac insufficiency or pulmonary hypertonia, or, for example, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency and diabetes. Compounds of the formula I can additionally be used in<!-- EPO <DP n="31"> --> the therapy of cirrhosis of the liver and also for improving a restricted memory performance or ability to learn.</p><p id="p0047" num="0047">The compounds of the formula I and their physiologically acceptable salts can be administered to animals, preferably to mammals, and in particular to humans, as pharmaceuticals by themselves, in mixtures with one another or in the form of pharmaceutical preparations. A subject of the present invention therefore also are the compounds of the formula I and their physiologically acceptable salts for use as pharmaceuticals, their use for activating soluble guanylate cyclase, for normalizing a disturbed cGMP balance and in particular their use in the therapy and prophylaxis of the abovementioned syndromes as well as their use for preparing medicaments for these purposes. Furthermore, a subject of the present invention are pharmaceutical preparations (or pharmaceutical compositions) which comprise as active component an effective dose of at least one compound of the formula I and/or a physiologically acceptable salt thereof and a customary pharmaceutically acceptable carrier, i. e. one or more pharmaceutically acceptable carrier substances and/or additives.<!-- EPO <DP n="32"> --></p><p id="p0048" num="0048">The pharmaceuticals according to the invention can be administered orally, for example in the form of pills, tablets, lacquered tablets, sugar-coated tablets, granules, hard and soft gelatin capsules, aqueous, alcoholic or oily solutions, syrups, emulsions or suspensions, or rectally, for example in the form of suppositories. Administration can also be carried out parenterally, for example subcutaneously, intramuscularly or intravenously in the form of solutions for injection or infusion. Other suitable administration forms are, for example, percutaneous or topical administration, for example in the form of ointments, tinctures, sprays or transdermal therapeutic systems, or the inhalative administration in the form of nasal sprays or aerosol mixtures, or, for example, microcapsules, implants or rods. The preferred administration form depends, for example, on the disease to be treated and on its severity.</p><p id="p0049" num="0049">The amount of active compound of the formula I and/or its physiologically acceptable salts in the pharmaceutical preparations normally is from 0.2 to 500 mg, preferably from1 to 200 mg, per dose, but depending on the type of the pharmaceutical preparation it can also be higher. The pharmaceutical preparations usually comprise 0.5 to 90 percent by weight of the compounds of the formula I and/or their physiologically acceptable salts. The preparation of the pharmaceutical preparations can be carried out in a manner known per se. For this purpose, one or more compounds of the formula I and/or their physiologically acceptable salts, together with one or more solid or liquid pharmaceutical carrier substances and/or additives (or auxiliary substances) and, if desired, in combination with other pharmaceutically active compounds having therapeutic or prophylactic action, are brought into a suitable administration form or dosage form which can then be used as a pharmaceutical in human or veterinary medicine.<!-- EPO <DP n="33"> --></p><p id="p0050" num="0050">For the production of pills, tablets, sugar-coated tablets and hard gelatin capsules it is possible to use, for example, lactose, starch, for example maize starch, or starch derivatives, talc, stearic acid or its salts. Carriers for soft gelatin capsules and suppositories are, for example, fats, waxes, semisolid and liquid polyols, natural or hardened oils. Suitable carriers for the preparation of solutions, for example of solutions for injection, or of emulsions or syrups are, for example, water, physiologically sodium chloride solution, alcohols such as ethanol, glycerol, polyols, sucrose, invert sugar, glucose, mannitol, vegetable oils. It is also possible to lyophilize the compounds of the formula I and their physiologically acceptable salts and to use the resulting lyophilisates, for example, for preparing preparations for injection or infusion. Suitable carriers for microcapsules, implants or rods are, for example, copolymers of glycolic acid and lactic acid.</p><p id="p0051" num="0051">Besides the active compounds and carriers, the pharmaceutical preparations can also contain customary additives, for example fillers, disintegrants, binders, lubricants, wetting agents, stabilizers, emulsifiers, dispersants, preservatives, sweeteners, colorants, flavorings, aromatizers, thickeners, diluents, buffer substances, solvents, solubilizers, agents for achieving a depot effect, salts for altering the osmotic pressure, coating agents or antioxidants.</p><p id="p0052" num="0052">The dosage of the active compound of the formula I to be administered and/or of a physiologically acceptable salt thereof depends on the individual case and is, as is customary, to be adapted to the individual circumstances to achieve an optimum effect. Thus, it depends on the nature and the severity of the disorder to be treated, and also on the sex, age, weight and individual responsiveness of the human or animal to be treated, on the efficacy and duration of action of the compounds used, on whether the therapy is acute or chronic or prophylactic, or on whether other active compounds are administered in addition to compounds of the formula I. In general, a daily dose of approximately 0.01 to 100 mg/kg, preferably 0.1 to 10 mg/kg, in particular 0.3 to 5 mg/kg (in each case mg per kg of bodyweight) is appropriate for administration to an adult weighing approximately 75 kg in order to obtain the<!-- EPO <DP n="34"> --> desired results. The daily dose can be administered in a single dose or, in particular when larger amounts are administered, be divided into several, for example two, three or four individual doses. In some cases, depending on the individual response, it may be necessary to deviate upwards or downwards from the given daily dose.</p><p id="p0053" num="0053">The compounds of the formula I activate the soluble guanylate cyclase, mainly by binding in the heme binding pocket of the enzyme. On account of this property, apart from use as pharmaceutically active compounds in human medicine and veterinary medicine, they can also be employed as a scientific tool or as aids for biochemical investigations in which such an effect on guanylate cyclase is intended, and also for diagnostic purposes, for example in the in vitro diagnosis of cell samples or tissue samples. The compounds of the formula I and salts thereof can furthermore be employed, as already mentioned above, as intermediates for the preparation of other pharmaceutically active compounds.</p><p id="p0054" num="0054">The following examples of compounds of the formula I and of intermediates for their preparation illustrate the invention, where all compounds in which the group A<sup>1</sup> is not a heteroarylene group but a phenylene group, are reference examples only and are not a subject of the invention as claimed herein.</p><heading id="h0001">Examples</heading><heading id="h0002">1.) 2-(4-Chloro-phenylsulfonylamino)-4,5-dimethoxy-benzoic acid</heading><p id="p0055" num="0055">33.71 g (0.32 mol) of sodium carbonate were dissolved in 250 ml of water and warmed to 60 °C. 25.00 g (0.13 mol) of 2-amino-4,5-dimethoxy-benzoic acid were introduced into the solution, and to this solution 29.55 g (0.14 mol) of 4-chlorobenzenesulfonyl chloride were added portionwise over 15 min. After cooling the mixture was filtered with suction, the residue was taken up in 1 % sodium hydrogencarbonate solution, the solution filtered, and the product precipitated by addition of 1 N hydrochloric acid. 25.90 g (55 %) of 2-(4-chloro-phenylsulfonylamino)-4,5-dimethoxy-benzoic<!-- EPO <DP n="35"> --> acid of melting point (m.p.) 212-214 °C were obtained.</p><p id="p0056" num="0056">Analogously were obtained:
<ul><li>2.) 5-Chloro-2-(4-chloro-phenylsulfonylamino)-benzoic acid; M.p.: 210 °C</li><li>3.) 5-Chloro-2-(3,4-dichloro-phenylsulfonylamino)-benzoic acid</li><li>6.) 2-(4-Chloro-phenylsulfonylamino)-5-methyl-benzoic acid; M.p.: 201 °C</li><li>7.) 3-(4-Chloro-phenylsulfonylamino)-thiophene-2-carboxylic acid; M.p.: 180 °C</li><li>8.) 3-(4-Chloro-phenylsulfonylamino)-pyrazole-4-carboxylic acid; Oil</li><li>9.) 2-(4-Chloro-phenylsulfonylamino)-pyridine-3-carboxylic acid; M.p.: Decomposition (dec.) &gt; 360 °C</li><li>10.) 2-(4-Chloro-phenylsulfonylamino)-4,5-dimethoxy-benzoyl chloride</li></ul></p><p id="p0057" num="0057">25.90 g (0.07 mol) of 2-(4-chloro-phenylsulfonylamino)-4,5-dimethoxy-benzoic acid were mixed with 75 ml of toluene, 17.30 g (0.08 mol) of phosphorus pentachloride were added and the mixture was stirred at 40-45 °C for 2.5 h. Then the mixture was concentrated in vacuo to half of its volume and the product that precipitated was filtered off with suction and washed with a small amount of toluene. 25.30 g (93 %) of 2-(4-chloro-phenylsulfonylamino)-4,5-dimethoxy-benzoyl chloride having a melting point of 175-177 °C were obtained.</p><p id="p0058" num="0058">Analogously were obtained:<!-- EPO <DP n="36"> -->
<ul><li>11.) 5-Chloro-2-(4-chloro-phenylsulfonylamino)-benzoyl chloride; M.p.: 127 °C</li><li>12.) 5-Chloro-2-(3,4-dichloro-phenylsulfonylamino)-benzoyl chloride; M.p.: 117 °C</li><li>14.) 2-(4-Chloro-phenylsulfonylamino)-5-methyl-benzoyl chloride; M.p.: 114 °C</li><li>15.) 3-(4-Chloro-phenylsulfonylamino)-thiophene-2-carboxylic acid chloride; M.p.: 122 °C</li><li>16.) 3-(4-Chloro-phenylsulfonylamino)-pyrazole-4-carboxylic acid chloride; M.p.: 260 °C. (Dec.)</li><li>17.) 2-(4-Chloro-phenylsulfonylamino)-pyridine-3-carboxylic acid chloride</li><li>18.) 4-((2-(4-Chloro-phenylsulfonylamino)-4,5-dimethoxy-benzoyl)-amino)-benzenesulfonyl fluoride</li></ul></p><p id="p0059" num="0059">10.00 g (25.6 mmol) of 2-(4-Chloro-phenylsulfonylamino)-4,5-dimethoxy-benzoyl chloride were mixed with 300 ml of toluene, 4.49 g (25.6 mmol) of 4-aminobenzenesulfonyl fluoride were added and the mixture was heated under reflux for 4 h. After cooling the precipitated solid was filtered off with suction and washed with toluene. 11.71 g (87 %) of the title compound having a melting point of 216-219 °C were obtained.</p><p id="p0060" num="0060">Analogously were obtained:<!-- EPO <DP n="37"> -->
<ul><li>19.) 4-((5-Chloro-2-(4-chloro-phenylsulfonylamino)-benzoyl)-amino)-benzenesulfonyl fluoride; M.p.: 242 °C</li><li>20.) N-(4-Aminosulfonyl-phenyl)-5-chloro-2-(4-chloro-phenylsulfonylamino)-benzamide; M.p.: 260 °C</li><li>21.) 5-Chloro-2-(4-chloro-phenylsulfonylamino)-N-((4-(4-nitro-phenyl)-mercapto)-phenyl)-benzamide; M.p.: 255 °C</li><li>22.) 5-Chloro-2-(4-chloro-phenylsulfonylamino)-N-(4-(phenylmercapto)-phenyl)-benzamide; M.p.: 169 °C</li><li>23.) 5-Chloro-2-(4-chloro-phenylsulfonylamino)-N-(4-methylmercapto-phenyl)-benzamide; M.p.: 220 °C<!-- EPO <DP n="38"> --></li><li>29.) 4-((3-(4-Chloro-phenylsulfonylamino)-thiophene-2-carbonyl)-amino)-benzenesulfonyl fluoride; M.p.: 255 °C</li><li>30.) 5-Chloro-2-(4-chloro-phenylsulfonylamino)-N-(4-mercapto-phenyl)-benzamide; M.p.: 202 °C</li><li>31.) 4-((3-(4-Chloro-phenylsulfonylamino)-pyrazol-4-carbonyl)-amino)-benzenesulfonyl fluoride; M.p.: 251 °C</li><li>32.) 3-((5-Chloro-2-(4-chloro-phenylsulfonylamino)-benzoyl)-amino)-benzenesulfonyl fluoride; M.p.: 224 °C</li><li>33.) 4-(2-(4-Chloro-phenylsulfonylamino)-pyridine-3-carbonyl)-amino)-benzenesulfonyl fluoride; M.p.: 263-265 °C</li><li>34.) 5-Chloro-2-(4-chloro-phenylsulfonylamino)-N-(4-methyl-5-(thiomorpholine-4-sulfonyl)-thiazol-2-yl)-benzamide; M.p.: 265-267 °C<!-- EPO <DP n="39"> --></li><li>59.) 2-(4-Chloro-phenylsulfonylamino)-4,5-dimethoxy-N-(4-(thiomorpholine-4-sulfonyl)-phenyl)-benzamide</li></ul><!-- EPO <DP n="40"> --></p><p id="p0061" num="0061">500 mg (0.95 mmol) of 4-((2-(4-chloro-phenylsulfonylamino)-4,5-dimethoxy-benzoyl)-amino)-benzenesulfonyl fluoride were dissolved in 1 ml of thiomorpholine and heated to 90 °C for 30 min. For working up the mixture was poured onto 50 ml of ice/1 N hydrochloric acid, the precipitate was filtered off with suction, dried in a vacuum-drying chamber over phosphorus pentoxide and recrystallized from hexane/ethyl acetate. 378 mg (65 %) of the title compound having a melting point of 241 °C were obtained.</p><p id="p0062" num="0062">Analogously were obtained:
<ul><li>63.) 5-Chloro-2-(4-chloro-phenylsulfonylamino)-N-(4-(thiomorpholine-4-sulfonyl)-phenyl)-benzamide; M.p.: 246 °C</li><li>64.) 5-Chloro-2-(4-chloro-phenylsulfonylamino)-N-(4-(4-methyl-piperazine-1-sulfonyl)-phenyl)-benzamide; M.p.: 219 °C</li><li>65.) 5-Chloro-2-(4-chloro-phenylsulfonylamino)-N-(4-(2,6-dimethyl-morpholine-4-sulfonyl)-phenyl)-benzamide; M.p.: 259 °C</li><li>66.) 5-Chloro-2-(4-chloro-phenylsulfonylamino)-N-(4-(cis-2,6-dimethyl-morpholine-4-sulfonyl)-phenyl)-benzamide; M.p.: 251 °C<!-- EPO <DP n="41"> --></li><li>73.) 5-Chloro-2-(4-chloro-phenylsulfonylamino)-N-(4-(4-(2-hydroxy-ethyl)-piperazine-1-sulfonyl)-phenyl)-benzamide; M.p.: 277 °C</li><li>75.) 5-Chloro-2-(4-chloro-phenylsulfonylamino)-N-(4-diethylsulfamoyl-phenyl)-benzamide; M.p.: 226 °C</li><li>76.) 5-Chloro-2-(4-chloro-phenylsulfonylamino)-N-(4-(piperidine-1-sulfonyl)-phenyl)-benzamide; M.p.: 240 °C<!-- EPO <DP n="42"> --></li><li>77.) 5-Chloro-2-(4-chloro-phenylsulfonylamino)-N-(4-(2-methoxy-ethylsulfamoyl)-phenyl)-benzamide; M.p.: 209 °C</li><li>78.) 2-(4-Chloro-phenylsulfonylamino)-5-methyl-N-(4-(morpholine-4-sulfonyl)-phenyl)-benzamide; M.p.: 203 °C</li><li>79.) 3-(4-Chloro-phenylsulfonylamino)-N-(4-(morpholine-4-sulfonyl)-phenyl)-thiophene-2-carboxamide; M.p.: 220 °C</li><li>84.) 3-(4-Chloro-phenylsulfonylamino)-N-(4-(thiomorpholine-4-sulfonyl)-phenyl)-thiophene-2-carboxamide; M.p.: 229 °C</li><li>85.) 5-Chloro-2-(4-chloro-phenylsulfonylamino)-N-(4-(morpholine-4-sulfonyl)-phenyl)-benzamide; M.p.: 228 °C</li><li>86.) 2-(4-Chloro-phenylsulfonylamino)-5-methyl-N-(4-(thiomorpholine-4-sulfonyl)-phenyl)-benzamide; M:p.: 234 °C<!-- EPO <DP n="43"> --></li><li>87.) 2-(4-Chloro-phenylsulfonylamino)-4,5-dimethoxy-N-(4-(4-methyl-piperazine-1-sulfonyl)-phenyl)-benzamide; M.p.: 172 °C</li><li>88.) 2-(4-Chloro-phenylsulfonylamino)-N-(4-(cis-2,6-dimethyl-morpholine-4-sulfonyl)-phenyl)-4,5-dimethoxy-benzamide; M.p.: 208 °C</li><li>89.) 2-(4-Chloro-phenylsulfonylamino)-N-(4-(4-hydroxy-piperidine-1-sulfonyl)-phenyl)-4,5-dimethoxy-benzamide; M.p.: 244 °C<!-- EPO <DP n="44"> --></li><li>107.) 2-{4-Chloro-phenylsulfonylamino)-N-(4-cyclopropylsulfamoyl-phenyl)-4,5-dimethoxy-benzamide; M.p.: 222 °C</li><li>108.) 2-(4-Chloro-phenylsulfonylamino)-N-(4-(3-hydroxy-pyrrolidine-1-sulfonyl)-phenyl)-4,5-dimethoxy-benzamide; M.p.: 272 °C</li><li>109.) N-(4-(Allyl-cyclohexyl-sulfamoyl)-phenyl)-2-(4-chloro-phenylsulfonylamino)-4,5-dimethoxy-benzamide; M.p.: 182 °C</li><li>111.) 5-Chloro-2-nitro-benzoyl chloride</li></ul></p><p id="p0063" num="0063">100.00 g (0.50 mol) of 5-chloro-2-nitrobenzoic acid were mixed with 72.20 g (0.61 mol) of thionyl chloride and the mixture was heated under reflux for 2 h. The excess thionyl chloride was removed in vacuo. 106.50 g (ca. 98 %) of crude 5-chloro-2-nitrobenzoyl chloride were obtained as an oil.</p><p id="p0064" num="0064">Analogously was obtained:
<ul><li>112.) 5-Methyl-2-nitro-benzoyl chloride; Oil</li><li>113.) 4-(5-Chloro-2-nitro-benzoylamino)-benzenesulfonyl fluoride</li></ul></p><p id="p0065" num="0065">86.00 g (0.39 mol) of 5-chloro-2-nitro-benzoyl chloride was dissolved in 300 ml of toluene, a solution of 62.00 g (0.35 mol) of 4-aminobenzenesulfonyl fluoride was added dropwise, and the mixture was heated under reflux for 4 h. Subsequently it was cooled, concentrated in vacuo to half of its volume, cooled, and the precipitated solid was filtered off with suction. 121.60 g (86 %) of the title compound having a melting point of 182-184 °C were obtained.<!-- EPO <DP n="45"> --></p><p id="p0066" num="0066">Analogously were obtained:
<ul><li>114.) 4-(5-Methyl-2-nitro-benzoylamino)-benzenesulfonyl fluoride; M.p.: 179 °C</li><li>115.) 5-Chloro-N-(4-ethylmercapto-phenyl)-2-nitro-benzamide</li><li>116.) 5-Chloro-N-(4-(morpholine-4-sulfonyl)-phenyl)-2-nitro-benzamide</li></ul></p><p id="p0067" num="0067">120.00 g (0.33 mol) of 4-(5-chloro-2-nitro-benzoylamino)-benzenesulfonyl fluoride, 29.10 g (0.33 mol) of morpholine and 33.85 g (0.33 mol) of triethylamine were stirred in 1200 ml of toluene at 60 °C for 2 days. The precipitated solid was filtered off with suction and recrystallized from acetone/n-hexane. 102.10 g (71 %) of the title compound having a melting point of 243-245 °C were obtained.</p><p id="p0068" num="0068">Analogously were obtained:
<ul><li>117.) 5-Chloro-2-nitro-N-(4-(thiomorpholine-4-sulfonyl)-phenyl)-benzamide; M.p.: 120 °C</li><li>118.) 5-Methyl-N-(4-(morpholine-4-sulfonyl)-phenyl)-2-nitro-benzamide; M.p.: 249 °C</li></ul>
<ul><li>120.) 2-Amino-5-chloro-N-(4-(morpholine-4-sulfonyl)-phenyl)-benzamide 11.10 g (26.1 mmol) of 5-chloro-N-(4-(morpholine-4-sulfonyl)-phenyl)-2-nitrobenzamide were dissolved in 440 ml of tetrahydrofuran/methanol (1:1) and a solution of 27.23 g (156.4 mmol) of sodium dithionite in 330 ml of water was added dropwise. After stirring for 1 h at room temperature the organic solvents were removed in rotary evaporator, and the precipitated product was filtered off with suction and purified by chromatography over silica with methylene chloride/methanol (9:1). 5.68 g (55 %) of the title compound having a melting point of 229-231 °C were obtained.</li></ul><!-- EPO <DP n="46"> --></p><p id="p0069" num="0069">Analogously were obtained:
<ul><li>121.) 2-Amino-5-chloro-N-(4-(thiomorpholine-4-sulfonyl)-phenyl)-benzamide; M.p.: 177 °C</li><li>123.) 2-Amino-5-chloro-N-(4-ethylsulfonyl-phenyl)-benzamide; M.p.: 159-161 °C</li><li>124.) 5-Chloro-2-(5-chloro-1,3-dimethyl-1H-pyrazole-4-sulfonyl-amino)-N-(4-(thiomorpholine-4-sulfonyl)-phenyl)-benzamide</li></ul></p><p id="p0070" num="0070">250 mg (0.60 mmol) of 2-amino-5-chloro-N-(4-(thiomorpholine-4-sulfonyl)-phenyl)-benzamide were dissolved in 10 ml of dry pyridine, and a solution of 195 mg (0.85 mmol) 5-chloro-1,3-dimethyl-1 H-pyrazole-4-sulfonyl chloride in 5 ml of pyridine was added dropwise at 0 °C. After 2 h the mixture was poured onto ice, the precipitated solid was filtered off with suction and purified by chromatography over silica with methylene chloride/methanol (98:2). 250 mg (69 %) of the title compound having a melting point of 215-216 °C were obtained.</p><p id="p0071" num="0071">Analogously were obtained:<!-- EPO <DP n="47"> -->
<ul><li>125.) 5-Chloro-N-(4-(morpholine-4-sulfonyl)-phenyl)-2-(4-methyl-phenylsulfonylamino)-benzamide; M.p.: 214 °C</li><li>126.) 5-Chloro-2-(3,4-dimethoxy-phenylsulfonylamino)-N-(4-(morpholine-4-sulfonyl)-phenyl)-benzamide; M.p.: 245 °C</li><li>128.) 2-((4-Acetylamino-phenyl)-sulfonylamino)-5-chloro-N-(4-(morpholine-4-sulfonyl)-phenyl)-benzamide; M.p.: 198 °C</li><li>129.) 5-Chloro-2-(5-chloro-thiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)-phenyl)-benzamide; M.p.: 112 °C</li><li>130.) 5-Chloro-2-(5-chloro-1,3-dimethyl-pyrazole-4-sulfonyl-amino)-N-(4-(morpholine-4-sulfonyl)-phenyl)-benzamide; M.p.: 161 °C</li><li>131.) 5-Chloro-2-((1-methyl-imidazole-4-sulfonyl)-amino)-N-(4-(morpholine-4-sulfonyl)-phenyl)-benzamide; M.p.: 141 °C</li><li>132.) 5-Chloro-N-(4-(morpholine-4-sulfonyl)-phenyl)-2-(pyridine-3-sulfonylamino)-benzamide; M.p.: 222 °C<!-- EPO <DP n="48"> --></li><li>145.) 5-Chloro-2-(4,5-dibromo-thiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)-phenyl)-benzamide; M.p.: 232 °C</li><li>146.) 5-Chloro-2-(4-fluoro-phenylsulfonylamino)-N-(4-(morpholine-4-sulfonyl)-phenyl)-benzamide; M.p.: 245 °C</li><li>148.) 5-Chloro-2-(3-chloro-4-methoxy-phenylsulfonylamino)-N-(4-(morpholine-4-sulfonyl)-phenyl)-benzamide; M.p.: 274 °C</li><li>150.) 5-Chloro-N-(4-(morpholine-4-sulfonyl)-phenyl)-2-(2,4,6-trimethyl-phenylsulfonylamino)-benzamide; M.p.: 240 °C</li><li>151.) 5-Chloro-N-(4-(morpholine-4-sulfonyl)-phenyl)-2-(3-nitro-phenylsulfonylamino)-benzamide; M.p.: 220 °C</li><li>152.) 5-Chloro-2-(4-methoxy-phenylsulfonylamino)-N-(4-(morpholine-4-sulfonyl)-phenyl)-benzamide; M.p.: 269 °C<!-- EPO <DP n="49"> --></li><li>175.) 2-(4-Chloro-phenylsulfonylamino)-4,5-dimethoxy-N-(4-(1,1-dioxo-thiomorpholine-4-sulfonyl)-phenyl)-benzamide<br/>
and</li><li>176.) 2-(4-Chloro-phenylsulfonylamino)-4,5-dimethoxy-N-(4-(1-oxo-thiomorpholine-4-sulfonyl)-phenyl)-benzamide</li></ul></p><p id="p0072" num="0072">500 mg (0.82 mmol) of 2-(4-chloro-phenylsulfonylamino)-4,5-dimethoxy-N-(4-(thiomorpholine-4-sulfonyl)-phenyl)-benzamide in 50 ml of acetone were cooled to 0 °C. A solution of 371 mg (1.23 mmol) of 57 % m-chloroperbenzoic acid in 20 ml of acetone was added and the mixture was stirred at room temperature over night. For working up it was poured onto water/ice and the precipitate was filtered off with suction. The two products obtained as a mixture were separated by chromatography over silica with methylene chloride/methanol (97:3).</p><p id="p0073" num="0073">Analogously were obtained:
<ul><li>179.) 5-Chloro-2-(3,4-dichloro-phenylsulfonylamino)-N-(4-ethylsulfonyl-phenyl)-benzamide; M.p.: 240 °C<!-- EPO <DP n="50"> --></li><li>180.) 5-Chloro-N-(4-ethylsulfonyl-phenyl)-2-nitro-benzamide</li><li>183.) 5-Chloro-2-(4-chloro-phenylsulfonylamino)-N-(4-isopropylmercapto-phenyl)-benzamide</li></ul><!-- EPO <DP n="51"> --></p><p id="p0074" num="0074">1.00 g (2.21 mmol) of 5-chloro-2-(4-chloro-phenylsulfonylamino)-N-(4-mercaptophenyl)-benzamide were dissolved in 25 ml of dimethylformamide and 0.25 g (2.21 mmol) of potassium tert-butylate were added. The mixture was stirred at room temperature for 15 min, then 0.27 g (2.21 mmol) of isopropyl bromide were added dropwise, and the mixture was heated to 60 °C for 8 h. For working up it was poured onto water and extracted with ethyl acetate. The combined extracts were evaporated and the residue was purified by chromatography over silica with hexane/ethyl acetate (3:1). 420 mg (39 %) of the title compound having a melting point of 168-169 °C were obtained.
<ul><li>190.) 5-Chloro-2-(5-chloro-thiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)-phenyl)-benzamide sodium salt</li></ul><!-- EPO <DP n="52"> --></p><p id="p0075" num="0075">A mixture of 0.48 g finely powdered sodium hydroxide and 7 g of 5-chloro-2-(5-chloro-thiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)-phenyl)-benzamide in 250 ml of ethanol was brought into solution by short heating. Then the mixture was evaporated in vacuo, 50 ml of water were added and it was again evaporated in vacuo to dryness. This procedure was repeated twice. The resulting product was dried in vacuo at 50 °C. M.p.: 343 °C (Dec.)</p><p id="p0076" num="0076">Analogously to the above compounds the following example compounds were obtained:
<ul><li>191.) 4,5-Dimethoxy-2-(5-chloro-thiophene-2-sulfonylamino)-N-(4-(N-methyl-N-(pyridin-3-yl-methyl)-aminosulfonyl)-phenyl)-benzamide hydrochloride; M.p.: 214°C</li><li>192.) 5-Chloro-2-(4-chloro-phenylsulfonylamino)-N-(4-(morpholine-4-sulfonyl)-3-methyl-phenyl)-benzamide; M.p.: 192 °C</li><li>193.) 5-Chloro-2-(4-chloro-phenylsulfonylamino)-N-(4-(cis-2,6-dimethyl-morpholine-4-sulfonyl)-3-methyl-phenyl)-benzamide; M.p.: 254 °C</li><li>194.) 5-Chloro-2-(4-chloro-phenylsulfonylamino)-N-(4-(3,5-dimethyl-piperidine-1-sulfonyl)-3-methyl-phenyl)-benzamide; M.p.: 242 °C</li><li>195.) 5-Chloro-2-(4-chloro-phenylsulfonylamino)-N-(4-(piperidine-1-sulfonyl)-3-methyl-phenyl)-benzamide; M.p.: 189 °C</li><li>196.) 4,5-Dimethoxy-2-(3,5-dimethyl-isoxazole-4-sulfonylamino)-N-(4-(N-methyl-N-(pyridin-3-yl-methyl)-aminosulfonyl)-phenyl)-benzamide; M.p.: 213 °C<!-- EPO <DP n="53"> --></li><li>210.) 6-Methyl-2-(4-chloro-phenylsulfonylamino)-N-(4-(perhydroazepine-1-sulfonyl)-phenyl)-benzamide; M.p.: 151 °C</li><li>211.) 6-Chloro-2-(4-chloro-phenylsulfonylamino)-N-(4-(pyrrolidine-1-sulfonyl)-phenyl)-benzamide; M.p.: 217 °C</li><li>216.) 4,5-Difluoro-2-(4-chloro-phenylsulfonylamino)-N-(4-(4-aminocarbonyl-piperidine-1-sulfonyl)-phenyl)-benzamide; M.p.: 227 °C<!-- EPO <DP n="54"> --></li><li>224.) 5-Chloro-2-(3,5-dimethyl-isoxazole-4-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)-phenyl)-benzamide; M.p.: 286 °C</li><li>225.) 5-Chloro-2-(5-chloro-thiophene-2-sulfonylamino)-N-(4-phenylsulfonyl)-phenyl)-benzamide; M.p.: 227 °C</li><li>226.) 4-Chloro-2-(4-chloro-phenylsulfonylamino)-N-(4-(cis-2,6-dimethyl-morpholine-4-sulfonyl)-phenyl)-benzamide; M.p.: 103 °C</li></ul><!-- EPO <DP n="55"> --></p><heading id="h0003">Pharmacological investigations</heading><heading id="h0004">1) Activation of the soluble guanylate cyclase</heading><p id="p0077" num="0077">The activation of the soluble guanylate cyclase (sGC) which catalyzes the conversion of guanosine triphosphate (GTP) into cyclic guanosine monophosphate (cGMP) and pyrophosphate, by the compounds according to the invention was quantified with the aid of an enzyme immunoassay (EIA) from Amersham. For this purpose the substances to be tested were initially incubated with sGC in microtiter plates, and the amount of the cGMP formed was then determined.</p><p id="p0078" num="0078">The sGC which was employed had been isolated from bovine lung (see <nplcit id="ncit0015" npl-type="s"><text>Methods in Enzymology, Volume 195, p. 377</text></nplcit>). The test solutions (100 µl per well) contained 50 mM triethanolamine (TEA) buffer (pH 7.5), 3 mM MgCl<sub>2</sub>, 3 mM reduced glutathione (GSH), 0.1 mM GTP, 1 mM 3-isobutyl-1-methylxanthine (IBMX), suitably diluted enzyme solution and the substance to be tested or, in the control experiments, the solvent. The substances to be tested were dissolved in dimethyl sulfoxide (DMSO) and the solution was diluted with DMSO/water, so that the final concentration c of the substance to be tested in the test solution had the value indicated in the table. The DMSO concentration in the test solution was 5 % (v/v). The reaction was initiated by addition of the sGC. The reaction mixture was incubated at 37 °C for 15 to 20 minutes and then stopped by ice-cooling and addition of the stop reagent (50 mM EDTA, pH 8.0). An aliquot of 50 µl was taken and used for determining the cGMP content using the acetylation protocol of the Amersham cGMP-EIA kit. The absorption of the samples was measured at 450 nm (reference wavelength 620 nm) in a microtiter plate reader. The cGMP concentration was determined using a standard curve which was obtained under the same test conditions. The activation of sGC by a test substance is given as the n-fold stimulation of the basal enzyme activity which was found in the control experiments (using solvent instead of test substance) (calculated using the formula<!-- EPO <DP n="56"> --> <maths id="math0001" num=""><math display="block"><mi mathvariant="normal">n</mi><mo>-</mo><mi>fold</mi><mspace width="1em"/><mi>stimulation</mi><mo>=</mo><msub><mfenced open="[" close="]" separators=""><mi>cGMP</mi></mfenced><mrow><mi>test</mi><mspace width="1em"/><mi>subs</mi><mo>⁢</mo><mi>tan</mi><mi mathvariant="normal">c</mi><mo>⁢</mo><mi mathvariant="normal">e</mi></mrow></msub><mo>/</mo><msub><mfenced open="[" close="]" separators=""><mi>cGMP</mi></mfenced><mi>control</mi></msub><mrow><mo>)</mo></mrow><mn mathvariant="normal">.</mn></math><img id="ib0009" file="imgb0009.tif" wi="118" he="11" img-content="math" img-format="tif"/></maths></p><p id="p0079" num="0079">The following results were obtained for reference examples specified above:
<tables id="tabl0001" num="0001"><table frame="none"><tgroup cols="3" colsep="0" rowsep="0"><colspec colnum="1" colname="col1" colwidth="56mm"/><colspec colnum="2" colname="col2" colwidth="34mm"/><colspec colnum="3" colname="col3" colwidth="29mm"/><thead><row><entry align="center" valign="top">Compound of reference example no.</entry><entry align="center" valign="top">concentration c [µM]</entry><entry align="center" valign="top">n-fold stimulation</entry></row></thead><tbody><row><entry align="center">23</entry><entry align="center">50</entry><entry align="center">14.7</entry></row><row><entry align="center">59</entry><entry align="center">50</entry><entry align="center">34.8</entry></row><row><entry align="center">63</entry><entry align="center">50</entry><entry align="center">33.9</entry></row><row><entry align="center">64</entry><entry align="center">50</entry><entry align="center">23.9</entry></row><row><entry align="center">65</entry><entry align="center">50</entry><entry align="center">24.6</entry></row><row><entry align="center">66</entry><entry align="center">50</entry><entry align="center">33</entry></row><row><entry align="center">73</entry><entry align="center">50</entry><entry align="center">16.5</entry></row><row><entry align="center">75</entry><entry align="center">50</entry><entry align="center">5.1</entry></row><row><entry align="center">76</entry><entry align="center">50</entry><entry align="center">10.6</entry></row><row><entry align="center">77</entry><entry align="center">50</entry><entry align="center">5.9</entry></row><row><entry align="center">79</entry><entry align="center">50</entry><entry align="center">15.4</entry></row><row><entry align="center">84</entry><entry align="center">50</entry><entry align="center">23.7</entry></row><row><entry align="center">86</entry><entry align="center">50</entry><entry align="center">32.9</entry></row><row><entry align="center">87</entry><entry align="center">50</entry><entry align="center">12.5</entry></row><row><entry align="center">88</entry><entry align="center">50</entry><entry align="center">24.4</entry></row><row><entry align="center">89</entry><entry align="center">50</entry><entry align="center">11.6</entry></row><row><entry align="center">124</entry><entry align="center">50</entry><entry align="center">31.2</entry></row><row><entry align="center">129</entry><entry align="center">50</entry><entry align="center">8.6</entry></row><row><entry align="center">130</entry><entry align="center">50</entry><entry align="center">35.3</entry></row><row><entry align="center">132</entry><entry align="center">50</entry><entry align="center">9.9</entry></row><row><entry align="center">145</entry><entry align="center">50</entry><entry align="center">8</entry></row><row><entry align="center">146</entry><entry align="center">50</entry><entry align="center">10.2</entry></row><row><entry align="center">148</entry><entry align="center">50</entry><entry align="center">15.5</entry></row><row><entry align="center">150</entry><entry align="center">50</entry><entry align="center">15.3</entry></row><!-- EPO <DP n="57"> --><row><entry align="center">151</entry><entry align="center">50</entry><entry align="center">19.9</entry></row><row><entry align="center">176</entry><entry align="center">50</entry><entry align="center">13.9</entry></row><row><entry align="center">191</entry><entry align="center">10</entry><entry align="center">27.5</entry></row><row><entry align="center">192</entry><entry align="center">10</entry><entry align="center">26.7</entry></row><row><entry align="center">193</entry><entry align="center">10</entry><entry align="center">31.1</entry></row><row><entry align="center">194</entry><entry align="center">5</entry><entry align="center">20.0</entry></row><row><entry align="center">195</entry><entry align="center">10</entry><entry align="center">16.2</entry></row><row><entry align="center">196</entry><entry align="center">10</entry><entry align="center">21.9</entry></row><row><entry align="center">224</entry><entry align="center">50</entry><entry align="center">27.8</entry></row><row><entry align="center">225</entry><entry align="center">10</entry><entry align="center">13.4</entry></row><row><entry align="center">226</entry><entry align="center">25</entry><entry align="center">3.3</entry></row></tbody></tgroup></table></tables></p><heading id="h0005">2) Relaxation of rat aorta</heading><p id="p0080" num="0080">For this test, normotensive male Wistar-Kyoto rats were sacrificed by a blow to the neck. The abdominal cavity and the thorax were opened by a medium sternotomy. The descending aorta was subsequently removed, freed of connective tissue and divided into 8 rings of a length of approximately 4 mm. The tip of a pair of tweezers was introduced into the lumen of 4 of the 8 rings. The endothelium was removed by carefully rolling the rings over the tip of the pair of tweezers. All 8 aorta rings (4 with endothelium and 4 without endothelium) were subsequently suspended in an organ bath (Schuler-Organbad; Hugo Sachs Elektronik) at a constant temperature of 37 °C for the isometric determination of the contractile tone. For 30 minutes, the rings were calibrated at a resting tension of 1 g in carbonated (95 % O<sub>2</sub>; 5 % CO<sub>2</sub>) Krebs-Henseleit solution (composition: Na<sup>+</sup> 144.0 mM; K<sup>+</sup> 5.9 mM; Cl<sup>-</sup> 126.9 mM; Ca<sup>2+</sup> 1.6 mM; Mg<sup>2+</sup> 1.2 mM; H<sub>2</sub>PO<sub>4</sub><sup>-</sup> 1.2 mM; SO<sub>4</sub><sup>2-</sup> 1.2 mM; HCO<sub>3</sub><sup>-</sup> 25.0 mM; D-glucose 11.1 mM) of pH 7.4. Additionally, 1 µmol/l of indomethacin were added to the Krebs-Henseleit solution to inhibit prostaglandin biosynthesis. The rings were subsequently precontracted by addition of phenylephrine (concentration in the solution: 1 µM) and<!-- EPO <DP n="58"> --> the endothelium-dependent relaxation or the functional loss of the endothelium was tested by addition of acetylcholine (concentration in the solution: 1 µM). After a 30-minute washing period, the rings were then again precontracted by addition of phenylephrine (1 µM), and the relaxing action of the test substances of the formula I was determined by administration of cumulative doses of the latter. The data were evaluated by standard methods. Given is the concentration IC<sub>50</sub> by which contraction is inhibited by 50 % (50 % relaxation).</p><p id="p0081" num="0081">The following results were obtained for reference examples specified above:
<tables id="tabl0002" num="0002"><table frame="none"><tgroup cols="3" colsep="0" rowsep="0"><colspec colnum="1" colname="col1" colwidth="56mm"/><colspec colnum="2" colname="col2" colwidth="40mm"/><colspec colnum="3" colname="col3" colwidth="16mm"/><thead><row><entry align="center" valign="top">Compound of reference example no.</entry><entry align="center" valign="top"/><entry align="center" valign="top">IC<sub>50</sub></entry></row></thead><tbody><row><entry align="right">59</entry><entry>ring without endothelium</entry><entry align="center">0.27 µM</entry></row><row><entry align="right">59</entry><entry>ring with endothelium</entry><entry align="center">0.52 µM</entry></row><row><entry align="right">88</entry><entry>ring without endothelium</entry><entry align="center">0.29 µM</entry></row><row><entry align="right">88</entry><entry>ring with endothelium</entry><entry align="center">0.67 µM</entry></row><row><entry align="right">129</entry><entry>ring without endothelium</entry><entry align="center">0.31 µM</entry></row><row><entry align="right">129</entry><entry>ring with endothelium</entry><entry align="center">0.46 µM</entry></row></tbody></tgroup></table></tables></p><heading id="h0006">3) Hemodynamic effect in the pig</heading><p id="p0082" num="0082">Three pigs (German landrace) were anesthetized (Ketamine 20 mg/kg i.m., Methomidate 8 mg/kg i.p., Xylazine 2.5 mg/kg i.m. and Pentobarbital 25 mg/kg i.v. as a bolus plus 0.16 mg/kg per minute). The trachea was intubated and the animals were given artificial respiration with air. Oxygen was added to keep the blood gas parameters in the normal range. To record the blood pressure (BP; BP(s) = systolic blood pressure, BP(d) = diastolic blood pressure) by means of a Statham 23Db pressure transducer a catheter was inserted into the right A. Femoralis. The left ventricular pressure (LVP), the left ventricular end-diastolic pressure (LVEDP), the contractility (dP/dt) and the heart rate (HR) were determined with a Millar PC 350<!-- EPO <DP n="59"> --> catheter "tip manometer" which was inserted into the right ventricle. After a stabilization period of the hemodynamic parameters of 30 minutes the test substance was administered in the indicated dose into the exposed duodenum by means of a catheter. The determined data were evaluated according to standard methods. Given are the means and the standard deviations (M ± SEM) of the starting values and of the maximal changes of the individual parameters (= maximal effects).</p><p id="p0083" num="0083">The following results were obtained for reference example 88 specified above (dosage 10 mg/kg i.d.):
<tables id="tabl0003" num="0003"><table frame="none"><tgroup cols="4" colsep="0" rowsep="0"><colspec colnum="1" colname="col1" colwidth="36mm"/><colspec colnum="2" colname="col2" colwidth="24mm"/><colspec colnum="3" colname="col3" colwidth="30mm"/><colspec colnum="4" colname="col4" colwidth="37mm"/><thead><row><entry valign="top">Parameter</entry><entry align="center" valign="top">starting value</entry><entry align="center" valign="top">maximal alteration</entry><entry valign="top">duration of action (min)</entry></row></thead><tbody><row><entry>BP(s) (mm Hg)</entry><entry align="center">123 ± 26</entry><entry align="center">-23 ± 6</entry><entry>&gt; 180</entry></row><row><entry>BP(d) (mm Hg)</entry><entry align="center">83 ± 24</entry><entry align="center">-20 ± 8</entry><entry>&gt; 180</entry></row><row><entry>LVEDP (mm Hg)</entry><entry align="center">4 ± 0.6</entry><entry align="center">-1.3 ± 0.3</entry><entry>&gt; 180</entry></row><row><entry>dP/dt<sub>max</sub> (mm Hg/sec))</entry><entry align="center">1800 ± 289</entry><entry align="center">-633 ± 33</entry><entry>&gt; 180</entry></row><row><entry>HR (beats/min)</entry><entry align="center">98 ± 2</entry><entry align="center">-8 ± 2</entry><entry>&gt; 180</entry></row></tbody></tgroup></table></tables></p></description><claims mxw-id="PCLM56979893" lang="DE" load-source="patent-office"><!-- EPO <DP n="66"> --><claim id="c-de-01-0001" num="0001"><claim-text>Verbindung der Formel I
<chemistry id="chem0012" num="0012"><img id="ib0013" file="imgb0013.tif" wi="77" he="67" img-content="chem" img-format="tif"/></chemistry>
worin<br/>
A<sup>1</sup> einen zweiwertigen Heteroarylenrest darstellt, der unsubstituiert oder mit einem oder mehreren gleichen oder verschiedenen Substituenten aus der Reihe Halogen, (C<sub>1</sub>-C<sub>4</sub>)-Alkyl, CF<sub>3</sub>, -O-(C<sub>1</sub>-C<sub>4</sub>)-Alkyl und -CN substituiert sein kann;<br/>
der Ring A<sup>2</sup>, der die zwei Kohlenstoffatome umfasst, die die Gruppen R<sup>2</sup>-SO<sub>2</sub>-NH und C(=X)-NH- tragen, einen Benzolring, einen Pyridinring, einen Thiophenring oder einen Pyrazolring darstellt;<br/>
R<sup>1</sup>(C<sub>1</sub>-C<sub>7</sub>)-Alkyl darstellt; oder Phenyl darstellt, das mit einem oder mehreren, gleichen oder verschiedenen Substituenten aus der Reihe Halogen, (C<sub>1</sub>-C<sub>4</sub>)-Alkyl, Phenyl, CF<sub>3</sub>, NO<sub>2</sub>, -O-(C<sub>1</sub>-C<sub>4</sub>)-Alkyl, (C<sub>1</sub>-C<sub>2</sub>)-Alkylendioxy, NH<sub>2</sub>, -NH-CO-(C<sub>1</sub>-C<sub>4</sub>)-Alkyl, -CN, -CO-NH<sub>2</sub>, -CO-OH und -CO-O-(C<sub>1</sub>-C<sub>4</sub>)-Alkyl substituiert sein kann; oder, wenn die Zahl n in der Gruppe R<sup>1</sup>-S(O)<sub>n</sub>- 2 ist, auch NR<sup>5</sup>R<sup>6</sup> darstellt;<br/>
R<sup>2</sup> Aryl darstellt;<br/>
<!-- EPO <DP n="67"> -->R<sup>3</sup> einen oder mehrere gleiche oder verschiedene Reste aus der Reihe Wasserstoff, Halogen, CF<sub>3</sub>, -O-(C<sub>1</sub>-C<sub>4</sub>)-Alkyl, -CN und (C<sub>1</sub>-C<sub>4</sub>)-Alkyl bedeutet;<br/>
R<sup>5</sup> und R<sup>6</sup> unabhängig voneinander Wasserstoff, oder (C<sub>1</sub>-C<sub>9</sub>)-Alkyl, das unsubstituiert oder mit Aryl substituiert sein kann, oder (C<sub>2</sub>-C<sub>9</sub>)-Alkenyl, oder (C<sub>3</sub>-C<sub>9</sub>)-Cycloalkyl, oder (C<sub>1</sub>-C<sub>4</sub>)-Alkyl-O-(C<sub>1</sub>-C<sub>3</sub>)-alkyl- darstellen, oder zusammen mit dem Stickstoffatom, das R<sup>5</sup> und R<sup>6</sup> trägt, einen fünfgliedrigen bis siebengliedrigen, gesättigten oder teilweise ungesättigten Heterocyclus bilden, der zusätzlich zu dem Stickstoffatom, das die Gruppen R<sup>5</sup> und R<sup>6</sup> trägt, ein weiteres Ringheteroatom aus der Reihe N, O und S enthalten kann und der mit einem oder mehreren gleichen oder verschiedenen Resten aus der Reihe (C<sub>1</sub>-C<sub>3</sub>)-Alkyl, Hydroxy-(C<sub>1</sub>-C<sub>3</sub>)-alkyl-, Aryl, Carbamoyl, Hydroxy und Oxo substituiert sein kann;<br/>
Aryl Phenyl oder Heteroaryl darstellt, die alle mit einem oder mehreren gleichen oder verschiedenen Substituenten aus der Reihe Halogen, (C<sub>1</sub>-C<sub>4</sub>)-Alkyl, Phenyl, CF<sub>3</sub>, NO<sub>2</sub>, -O-(C<sub>1</sub>-C<sub>4</sub>)-Alkyl, (C<sub>1</sub>-C<sub>2</sub>)-Alkylendioxy, NH<sub>2</sub>, -NH-CO-(C<sub>1</sub>-C<sub>4</sub>)-Alkyl, -CN, -CO-NH<sub>2</sub>, -CO-OH und -CO-O-(C<sub>1</sub>-C<sub>4</sub>)-Alkyl substituiert sein können;<br/>
Heteroaryl und Heteroarylen einen Rest eines monocyclischen fünfgliedrigen oder sechsgliedrigen aromatischen Heterocyclus darstellen, der ein oder zwei gleiche oder verschiedene Ringheteroatome aus der Reihe N, O und S enthält;<br/>
n 0 oder 2 ist;<br/>
X Sauerstoff darstellt;<br/>
in allen ihren stereoisomeren Formen und Gemische davon in allen Verhältnissen, und ihre physiologisch verträglichen Salze;<br/>
wobei nur bis zu zwei Nitrogruppen in einer Verbindung der Formel I vorliegen dürfen.<!-- EPO <DP n="68"> --></claim-text></claim><claim id="c-de-01-0002" num="0002"><claim-text>Verbindung der Formel I nach Anspruch 1, worin<br/>
A' einen zweiwertigen Heteroarylenrest darstellt, der unsubstituiert oder mit einem oder mehreren gleichen oder verschiedenen Substituenten aus der Reihe Halogen, (C<sub>1</sub>-C<sub>4</sub>)-Alkyl, CF<sub>3</sub>, -O-(C<sub>1</sub>-C<sub>4</sub>)-Alkyl und -CN substituiert sein kann;<br/>
der Ring A<sup>2</sup>, der die zwei Kohlenstoffatome umfasst, die die Gruppen R<sup>2</sup>-SO<sub>2</sub>-NH und C(=X)-NH- tragen, einen Benzolring darstellt;<br/>
R<sup>1</sup> NR<sup>5</sup>R<sup>6</sup> darstellt;<br/>
R<sup>2</sup> Aryl darstellt;<br/>
R<sup>3</sup> einen oder mehrere gleiche oder verschiedene Reste aus der Reihe Wasserstoff, (C<sub>1</sub>-C<sub>3</sub>)-Alkyl, Halogen, (C<sub>1</sub>-C<sub>3</sub>)-Alkoxy und CF<sub>3</sub> bedeutet;<br/>
R<sup>5</sup> und R<sup>6</sup> zusammen mit dem Stickstoffatom, das R<sup>5</sup> und R<sup>6</sup> trägt, einen fünfgliedrigen, sechsgliedrigen oder siebengliedrigen gesättigten Heterocyclus bilden, der zusätzlich zu dem Stickstoffatom, das die Gruppen R<sup>5</sup> und R<sup>6</sup> trägt, ein weiteres Ringheteroatom aus der Reihe N, O und S enthalten kann und der mit einem oder mehreren gleichen oder verschiedenen Resten aus der Reihe (C<sub>1</sub>-C<sub>3</sub>)-Alkyl, Hydroxy-(C<sub>1</sub>-C<sub>3</sub>)-Alkyl-, Aryl, Carbamoyl, Hydroxy und Oxo substituiert sein kann;<br/>
Aryl Phenyl oder Heteroaryl darstellt, die alle mit einem oder mehreren gleichen oder verschiedenen Substituenten aus der Reihe Halogen, (C<sub>1</sub>-C<sub>4</sub>)-Alkyl, Phenyl, CF<sub>3</sub>, NO<sub>2</sub>, -O-(C<sub>1</sub>-C<sub>4</sub>)-Alkyl, (C<sub>1</sub>-C<sub>2</sub>)-Alkylendioxy, NH<sub>2</sub>, -NH-CO-(C<sub>1</sub>-C<sub>4</sub>)-Alkyl, -CN, -CO-NH<sub>2</sub>, -CO-OH und -CO-O-(C<sub>1</sub>-C<sub>4</sub>)-Alkyl substituiert sein können;<br/>
Heteroaryl und Heteroarylen einen Rest eines monocyclischen fünfgliedrigen oder sechsgliedrigen aromatischen Heterocyclus darstellen, der ein oder zwei gleiche oder verschiedene Ringheteroatome aus der Reihe N, O und S enthält;<br/>
n 2 ist;<br/>
<!-- EPO <DP n="69"> -->X Sauerstoff darstellt;<br/>
in allen ihren stereoisomeren Formen und Gemische davon in allen Verhältnissen, und ihre physiologisch verträglichen Salze.</claim-text></claim><claim id="c-de-01-0003" num="0003"><claim-text>Verbindung der Formel I nach Anspruch 1 und/oder Anspruch 2, worin A' einen zweiwertigen Pyridin-, Thiazol- oder Thiophenrest darstellt, in allen ihren stereoisomeren Formen und Gemische davon in allen Verhältnissen, und ihre physiologisch verträglichen Salze.</claim-text></claim><claim id="c-de-01-0004" num="0004"><claim-text>Verbindung der Formel I nach einem oder mehreren der Ansprüche 1 bis 3, worin A<sup>1</sup> einen fünfgliedrigen Heteroarylenrest darstellt, in allen ihren stereoisomeren Formen und Gemische davon in allen Verhältnissen, und ihre physiologisch verträglichen Salze.</claim-text></claim><claim id="c-de-01-0005" num="0005"><claim-text>Verbindung der Formel I nach einem oder mehreren der Ansprüche 1 bis 4, worin A<sup>1</sup> einen zweiwertigen Thiazolrest darstellt, in allen ihren stereoisomeren Formen und Gemische davon in allen Verhältnissen, und ihre physiologisch verträglichen Salze.</claim-text></claim><claim id="c-de-01-0006" num="0006"><claim-text>Verbindung der Formel I nach einem oder mehreren der Ansprüche 1 bis 5, worin der Ring A<sup>2</sup>, der die zwei Kohlenstoffatome umfasst, die die Gruppen R<sup>2</sup>-SO<sub>2</sub>-NH und C(=X)-NH- tragen, einen Benzolring darstellt, in allen ihren stereoisomeren Formen und Gemische davon in allen Verhältnissen, und ihre physiologisch verträglichen Salze.</claim-text></claim><claim id="c-de-01-0007" num="0007"><claim-text>Verbindung der Formel I nach einem oder mehreren der Ansprüche 1 bis 6, worin R<sup>1</sup> NR<sup>5</sup>R<sup>6</sup> darstellt;<br/>
R<sup>5</sup> und R<sup>6</sup> zusammen mit dem Stickstoffatom, das R<sup>5</sup> und R<sup>6</sup> trägt, einen fünfgliedrigen, sechsgliedrigen oder siebengliedrigen gesättigten Heterocyclus bilden, der zusätzlich zu dem Stickstoffatom, das die Gruppen R<sup>5</sup> und R<sup>6</sup> trägt, ein weiteres<!-- EPO <DP n="70"> --> Ringheteroatom aus der Reihe N, O und S enthalten kann und der mit einem oder mehreren gleichen oder verschiedenen Resten aus der Reihe (C<sub>1</sub>-C<sub>3</sub>)-Alkyl, Hydroxy-(C<sub>1</sub>-C<sub>3</sub>)-Alkyl-, Aryl, Carbamoyl, Hydroxy und Oxo substituiert sein kann;<br/>
n 2 ist;<br/>
in allen ihren stereoisomeren Formen und Gemische davon in allen Verhältnissen, und ihre physiologisch verträglichen Salze.</claim-text></claim><claim id="c-de-01-0008" num="0008"><claim-text>Verbindung der Formel I nach einem oder mehreren der Ansprüche 1 bis 7, worin R<sup>1</sup> NR<sup>5</sup>R<sup>6</sup> darstellt;<br/>
R<sup>5</sup> und R<sup>6</sup> zusammen mit dem Stickstoffatom, das R<sup>5</sup> und R<sup>6</sup> trägt, einen Heterocyclus aus der Reihe Morpholin, Thiomorpholin, 1,1-Dioxothiomorpholin, 1-Oxothiomorpholin und Dimethylmorpholine bilden,<br/>
n 2 ist;<br/>
in allen ihren stereoisomeren Formen und Gemische davon in allen Verhältnissen, und ihre physiologisch verträglichen Salze.</claim-text></claim><claim id="c-de-01-0009" num="0009"><claim-text>Verfahren zur Herstellung einer Verbindung der Formel I nach einem oder mehreren der Ansprüche 1 bis 8, umfassend das Umwandeln einer cyclischen Aminocarbonsäure der Formel II in eine Sulfonylaminocarbonsäure der Formel III und das Umwandeln der Verbindung der Formel III in eine Verbindung der Formel I,
<chemistry id="chem0013" num="0013"><img id="ib0014" file="imgb0014.tif" wi="156" he="65" img-content="chem" img-format="tif"/></chemistry><!-- EPO <DP n="71"> -->
oder das Umwandeln einer cyclischen Nitrocarbonsäure der Formel IX in ein Nitrocarboxamid der Formel XII und das Umwandeln der Verbindung der Formel XII in eine Verbindung der Formel I durch Reduktion der Nitrogruppe zu einer Aminogruppe und Sulfonylierung der Aminogruppe,
<chemistry id="chem0014" num="0014"><img id="ib0015" file="imgb0015.tif" wi="148" he="70" img-content="chem" img-format="tif"/></chemistry>
wobei in den Formeln I, II, III, IX und XII die Gruppen A<sup>1</sup>, A<sup>2</sup>, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> und X und n die in den Ansprüchen 1 bis 8 angegebenen Bedeutungen aufweisen oder Reste oder funktionelle Gruppen auch in geschützter Form oder in Form von Vorstufengruppen vorliegen können.</claim-text></claim><claim id="c-de-01-0010" num="0010"><claim-text>Verbindung der Formel I nach einem oder mehreren der Ansprüche 1 bis 8 und/oder ihre physiologisch verträglichen Salze zur Verwendung als Arzneimittel.</claim-text></claim><claim id="c-de-01-0011" num="0011"><claim-text>Pharmazeutische Zubereitung, die eine oder mehrere Verbindungen der Formel I nach einem oder mehreren der Ansprüche 1 bis 8 und/oder ihre physiologisch verträglichen Salze und einen pharmazeutisch verträglichen Träger umfasst.</claim-text></claim><claim id="c-de-01-0012" num="0012"><claim-text>Verbindung der Formel I nach einem oder mehreren der Ansprüche 1 bis 8 und/oder ihre physiologisch verträglichen Salze zur Verwendung als Aktivator der löslichen Guanylatcyclase.<!-- EPO <DP n="72"> --></claim-text></claim><claim id="c-de-01-0013" num="0013"><claim-text>Verbindung der Formel I nach einem oder mehreren der Ansprüche 1 bis 8 und/oder ihre physiologisch verträglichen Salze zur Verwendung bei der Therapie oder Prophylaxe von cardiovasculären Erkrankungen, endothelialer Dysfunktion, diastolischer Dysfunktion, Atherosklerose, Bluthochdruck, Angina pectoris, Thrombosen, Restenosen, Herzinfarkt, Schlaganfällen, Herzinsuffizienz, pulmonaler Hypertonie, erektiler Dysfunktion, Asthma bronchiale, chronischer Niereninsuffizienz, Diabetes oder Leberzirrhose oder zum Verbessern einer eingeschränkten Gedächtnisleistung oder Lernfähigkeit.</claim-text></claim></claims><claims mxw-id="PCLM56979894" lang="EN" load-source="patent-office"><!-- EPO <DP n="60"> --><claim id="c-en-01-0001" num="0001"><claim-text>A compound of the formula I,
<chemistry id="chem0009" num="0009"><img id="ib0010" file="imgb0010.tif" wi="69" he="62" img-content="chem" img-format="tif"/></chemistry>
wherein
<claim-text>A' is a divalent heteroarylene residue which can be unsubstituted or substituted by one or more identical or different substituents from the series halogen, (C<sub>1</sub>-C<sub>4</sub>)-alkyl, CF<sub>3</sub>, -O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl and -CN;</claim-text>
<claim-text>the ring A<sup>2</sup>, which comprises the two carbon atoms which carry the groups R<sup>2</sup>-SO<sub>2</sub>-NH and C(=X)-NH-, is a benzene ring, a pyridine ring, a thiophene ring or a pyrazole ring;</claim-text>
<claim-text>R<sup>1</sup> is (C<sub>1</sub>-C<sub>7</sub>)-alkyl; or is phenyl which can be substituted by one or more identical or different substituents from the series halogen, (C<sub>1</sub>-C<sub>4</sub>)-alkyl, phenyl, CF<sub>3</sub>, NO<sub>2</sub>, -O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, (C<sub>1</sub>-C<sub>2</sub>)-alkylenedioxy, NH<sub>2</sub>, -NH-CO-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, -CN, -CO-NH<sub>2</sub>, -CO-OH and -CO-O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl; or, if the number n in the group R<sup>1</sup>-S(O)<sub>n</sub>- is 2, also is NR<sup>5</sup>R<sup>6</sup>;</claim-text>
<claim-text>R<sup>2</sup> is aryl;<!-- EPO <DP n="61"> --></claim-text>
<claim-text>R<sup>3</sup> denotes one or more identical or different residues from the series hydrogen, halogen, CF<sub>3</sub>, -O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, -CN and (C<sub>1</sub>-C<sub>4</sub>)-alkyl;</claim-text>
<claim-text>R<sup>5</sup> and R<sup>6</sup>, independently of one another, are hydrogen, or (C<sub>1</sub>-C<sub>9</sub>)-alkyl which can be unsubstituted or substituted by aryl, or (C<sub>2</sub>-C<sub>9</sub>)-alkenyl, or (C<sub>3</sub>-C<sub>9</sub>)-cycloalkyl, or (C<sub>1</sub>-C<sub>4</sub>)-alkyl-O-(C<sub>1</sub>-C<sub>3</sub>)-alkyl-, or together with the nitrogen atom carrying R<sup>5</sup> and R<sup>6</sup> form a 5-membered to 7-membered, saturated or partially unsaturated heterocycle which, in addition to the nitrogen atom carrying the groups R<sup>5</sup> and R<sup>6</sup>, can contain one further ring heteroatom from the series N, O and S, and which can be substituted by one or more identical or different residues from the series (C<sub>1</sub>-C<sub>3</sub>)-alkyl, hydroxy-(C<sub>1</sub>-C<sub>3</sub>)-alkyl-, aryl, carbamoyl, hydroxy and oxo;</claim-text>
<claim-text>aryl is phenyl or heteroaryl which can all be substituted by one or more identical or different substituents from the series halogen, (C<sub>1</sub>-C<sub>4</sub>)-alkyl, phenyl, CF<sub>3</sub>, NO<sub>2</sub>, -O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, (C<sub>1</sub>-C<sub>2</sub>)-alkylenedioxy, NH<sub>2</sub>, -NH-CO-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, -CN, -CO-NH<sub>2</sub>, -CO-OH and -CO-O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl;</claim-text>
<claim-text>heteroaryl and heteroarylene are a residue of a monocyclic 5-membered or 6-membered aromatic heterocycle which contains one or two identical or different ring heteroatoms from the series N, O and S;</claim-text>
<claim-text>n is 0 or 2;</claim-text>
<claim-text>X is oxygen;</claim-text>
<claim-text>in all its stereoisomeric forms and mixtures thereof in all ratios, and its physiologically acceptable salts;</claim-text>
<claim-text>where only up to two nitro groups can be present in a compound of the formula I.</claim-text></claim-text></claim><claim id="c-en-01-0002" num="0002"><claim-text>A compound of the formula I as claimed in claim 1, wherein<!-- EPO <DP n="62"> -->
<claim-text>A' is a divalent heteroarylene residue which can be unsubstituted or substituted by one or more identical or different substituents from the series halogen, (C<sub>1</sub>-C<sub>4</sub>)-alkyl, CF<sub>3</sub>, -O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl and -CN;</claim-text>
<claim-text>the ring A<sup>2</sup>, which comprises the two carbon atoms which carry the groups R<sup>2</sup>-SO<sub>2</sub>-NH and C(=X)-NH-, is a benzene ring;</claim-text>
<claim-text>R' is NR<sup>5</sup>R<sup>6</sup>;</claim-text>
<claim-text>R<sup>2</sup> is aryl;</claim-text>
<claim-text>R<sup>3</sup> denotes one or more identical or different residues from the series hydrogen, (C<sub>1</sub>-C<sub>3</sub>)-alkyl, halogen, (C<sub>1</sub>-C<sub>3</sub>)-alkoxy and CF<sub>3</sub>;</claim-text>
<claim-text>R<sup>5</sup> and R<sup>6</sup> together with the nitrogen atom carrying R<sup>5</sup> and R<sup>6</sup> form a 5-membered, 6-membered or 7-membered saturated heterocycle which, in addition to the nitrogen atom carrying the groups R<sup>5</sup> and R<sup>6</sup>, can contain one further ring heteroatom from the series N, O and S, and which can be substituted by one or more identical or different residues from the series (C<sub>1</sub>-C<sub>3</sub>)-alkyl, hydroxy-(C<sub>1</sub>-C<sub>3</sub>)-alkyl-, aryl, carbamoyl, hydroxy and oxo;</claim-text>
<claim-text>aryl is phenyl or heteroaryl which can all be substituted by one or more identical or different substituents from the series halogen, (C<sub>1</sub>-C<sub>4</sub>)-alkyl, phenyl, CF<sub>3</sub>, NO<sub>2</sub>, -O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, (C<sub>1</sub>-C<sub>2</sub>)-alkylenedioxy, NH<sub>2</sub>, -NH-CO-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, -CN, -CO-NH<sub>2</sub>, -CO-OH and -CO-O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl;</claim-text>
<claim-text>heteroaryl and heteroarylene are a residue of a monocyclic 5-membered or 6-membered aromatic heterocycle which contains one or two identical or different ring heteroatoms from the series N, O and S;</claim-text>
<claim-text>n is 2;<!-- EPO <DP n="63"> --></claim-text>
<claim-text>X is oxygen;</claim-text>
<claim-text>in all its stereoisomeric forms and mixtures thereof in all ratios, and its physiologically acceptable salts.</claim-text></claim-text></claim><claim id="c-en-01-0003" num="0003"><claim-text>A compound of the formula I as claimed in claim 1 and/or claim 2, wherein A' is a divalent residue of pyridine, thiazole or thiophene, in all its stereoisomeric forms and mixtures thereof in all ratios, and its physiologically acceptable salts.</claim-text></claim><claim id="c-en-01-0004" num="0004"><claim-text>A compound of the formula I as claimed in one or more of claims 1 to 3, wherein A<sup>1</sup> is a 5-membered heteroarylene residue, in all its stereoisomeric forms and mixtures thereof in all ratios, and its physiologically acceptable salts.</claim-text></claim><claim id="c-en-01-0005" num="0005"><claim-text>A compound of the formula I as claimed in one or more of claims 1 to 4, wherein A' is a divalent residue of thiazole, in all its stereoisomeric forms and mixtures thereof in all ratios, and its physiologically acceptable salts.</claim-text></claim><claim id="c-en-01-0006" num="0006"><claim-text>A compound of the formula I as claimed in one or more of claims 1 to 5, wherein the ring A<sup>2</sup>, which comprises the two carbon atoms which carry the groups R<sup>2</sup>-SO<sub>2</sub>-NH and C(=X)-NH-, is a benzene ring, in all its stereoisomeric forms and mixtures thereof in all ratios, and its physiologically acceptable salts.</claim-text></claim><claim id="c-en-01-0007" num="0007"><claim-text>A compound of the formula I as claimed in one or more of claims 1 to 6, wherein R<sup>1</sup> is NR<sup>5</sup>R<sup>6</sup>;<br/>
R<sup>5</sup> and R<sup>6</sup> together with the nitrogen atom carrying R<sup>5</sup> and R<sup>6</sup> form a 5-membered, 6-membered or 7-membered saturated heterocycle which, in addition to the nitrogen atom carrying the groups R<sup>5</sup> and R<sup>6</sup>, can contain one further ring heteroatom from the series N, O and S, and which can be substituted by one or more identical or different residues from the series (C<sub>1</sub>-C<sub>3</sub>)-alkyl, hydroxy-(C<sub>1</sub>-C<sub>3</sub>)-alkyl-, aryl, carbamoyl, hydroxy and oxo;<br/>
n is 2;<br/>
<!-- EPO <DP n="64"> -->in all its stereoisomeric forms and mixtures thereof in all ratios, and its physiologically acceptable salts.</claim-text></claim><claim id="c-en-01-0008" num="0008"><claim-text>A compound of the formula I as claimed in one or more of claims 1 to 7, wherein R' is NR<sup>5</sup>R<sup>6</sup>;<br/>
R<sup>5</sup> and R<sup>6</sup> together with the nitrogen atom carrying R<sup>5</sup> and R<sup>6</sup> form a heterocycle from the series morpholine, thiomorpholine, 1,1-dioxo-thiomorpholine, 1-oxo-thiomorpholine and dimethylmorpholines;<br/>
n is 2;<br/>
in all its stereoisomeric forms and mixtures thereof in all ratios, and its physiologically acceptable salts.</claim-text></claim><claim id="c-en-01-0009" num="0009"><claim-text>A process for the preparation of a compound of the formula I as claimed in one or more of claims 1 to 8, comprising converting a cyclic aminocarboxylic acid of the formula II into a sulfonylaminocarboxylic acid of the formula III and converting the compound of the formula III into a compound of the formula I,
<chemistry id="chem0010" num="0010"><img id="ib0011" file="imgb0011.tif" wi="140" he="62" img-content="chem" img-format="tif"/></chemistry>
or converting a cyclic nitrocarboxylic acid of the formula IX into a nitrocarboxamide of the formula XII and converting the compound of the formula XII into a compound of the formula I by reduction of the nitro group to an amino group and sulfonylation of the amino group,<!-- EPO <DP n="65"> -->
<chemistry id="chem0011" num="0011"><img id="ib0012" file="imgb0012.tif" wi="133" he="70" img-content="chem" img-format="tif"/></chemistry>
where in the formulae I, II, III, IX and XII the groups A<sup>1</sup>, A<sup>2</sup>, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and X and n have the meanings indicated in claims 1 to 8 or residues or functional groups can also be present in protected form or in the form of precursor groups.</claim-text></claim><claim id="c-en-01-0010" num="0010"><claim-text>A compound of the formula I as claimed in one or more of claims 1 to 8 and/or its physiologically acceptable salts for use as a pharmaceutical.</claim-text></claim><claim id="c-en-01-0011" num="0011"><claim-text>A pharmaceutical preparation, which comprises one or more compounds of the formula I as claimed in one or more of claims 1 to 8 and/or their physiologically acceptable salts and a pharmaceutically acceptable carrier.</claim-text></claim><claim id="c-en-01-0012" num="0012"><claim-text>A compound of the formula I as claimed in one or more of claims 1 to 8 and/or its physiologically acceptable salts for use as an activator of soluble guanylate cyclase.</claim-text></claim><claim id="c-en-01-0013" num="0013"><claim-text>A compound of the formula I as claimed in one or more of claims 1 to 8 and/or its physiologically acceptable salts for use in the therapy or prophylaxis of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, angina pectoris, thromboses, restenoses, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes or cirrhosis of the liver or for improving restricted memory performance or ability to learn.</claim-text></claim></claims><claims mxw-id="PCLM56979895" lang="FR" load-source="patent-office"><!-- EPO <DP n="73"> --><claim id="c-fr-01-0001" num="0001"><claim-text>Composé de formule I
<chemistry id="chem0015" num="0015"><img id="ib0016" file="imgb0016.tif" wi="77" he="67" img-content="chem" img-format="tif"/></chemistry>
dans laquelle
<claim-text>A' est un résidu hétéroarylène divalent qui peut être non substitué ou substitué par un ou plusieurs substituants identiques ou différents de la série halogène, alkyle en C<sub>1</sub>-C<sub>4</sub>, CF<sub>3</sub>, -O-alkyle en C<sub>1</sub>-C<sub>4</sub> et -CN ;</claim-text>
<claim-text>le noyau A<sup>2</sup>, qui comprend les deux atomes de carbone qui portent les groupes R<sup>2</sup>-SO<sub>2</sub>-NH et C(=X)-NH-, est un noyau benzène, un noyau pyridine, un noyau thiophène ou un noyau pyrazole ;</claim-text>
<claim-text>R<sup>1</sup> est un groupe alkyle en C<sub>1</sub>-C<sub>7</sub>; ou est un groupe phényle qui peut être substitué par un ou plusieurs substituants identiques ou différents de la série halogène, alkyle en C<sub>1</sub>-C<sub>4</sub>, phényle, CF<sub>3</sub>, NO<sub>2</sub>, -O-alkyle en C<sub>1</sub>-C<sub>4</sub>, alkylène(en C<sub>1</sub>-C<sub>2</sub>)dioxy, NH<sub>2</sub>, -NH-CO-(alkyle en C<sub>1</sub>-C<sub>4</sub>), -CN, -CO-NH<sub>2</sub>, -CO-OH, et -CO-O-(alkyle en C<sub>1</sub>-O<sub>4</sub>); ou, si le nombre n dans le groupe R<sup>1</sup>-S(O)<sub>n</sub>- est égal à 2, il représente aussi NR<sup>5</sup>R<sup>6</sup> ;</claim-text>
<claim-text>R<sup>2</sup> est un groupe aryle ;</claim-text>
<claim-text>R<sup>3</sup> désigne un ou plusieurs résidus identiques ou différents de la série hydrogène, halogène, CF<sub>3</sub>, -O-alkyle en C<sub>1</sub>-C<sub>4</sub>, -CN et alkyle en C<sub>1</sub>-C<sub>4</sub> ;</claim-text>
<claim-text>R<sup>5</sup> et R<sup>6</sup> indépendamment l'un de l'autre, sont des atomes d'hydrogène, ou des groupes alkyle en C<sub>1</sub>-C<sub>9</sub> qui peuvent être non substitués ou substitués par un groupe<!-- EPO <DP n="74"> --> aryle, ou alcényle en C<sub>2</sub>-C<sub>9</sub>, ou cycloalkyle en C<sub>3</sub>-C<sub>9</sub>, ou alkyle(en C<sub>1</sub>-C<sub>4</sub>)-O-alkyle (en C<sub>1</sub>-C<sub>3</sub>)-, ou bien conjointement avec l'atome d'azote portant les radicaux R<sup>5</sup> et R<sup>6</sup>, forment un hétérocycle allant de 5 chaînons à 7 chaînons, saturé ou partiellement insaturé, qui, en plus de l'atome d'azote portant les groupes R<sup>5</sup> et R<sup>6</sup>, peut contenir un autre hétéroatome dans le noyau de la série N, O et S, et qui peut être substitué par un ou plusieurs résidus identiques ou différents de la série alkyle en C<sub>1</sub>-C<sub>3</sub>, hydroxyalkyle en C<sub>1</sub>-C<sub>3</sub>, aryle, carbamoyle, hydroxy et oxo ;</claim-text>
<claim-text>le groupe aryle est un groupe phényle ou hétéroaryle, tous pouvant être substitués par un ou plusieurs substituants identiques ou différents de la série halogène, alkyle en C<sub>1</sub>-C<sub>4</sub>, phényle, CF<sub>3</sub>, NO<sub>2</sub>, -O-alkyle en C<sub>1</sub>-C<sub>4</sub>, alkylène(en C<sub>1</sub>-C<sub>2</sub>)dioxy, NH<sub>2</sub>, -NH-CO-(alkyle en C<sub>1</sub>-C<sub>4</sub>), -CN, -CO-NH<sub>2</sub>, -CO-OH et -CO-O-(alkyle en C<sub>1</sub>-C<sub>4</sub>) :
<claim-text>les groupes hétéroaryle et hétéroarylène sont un résidu d'un hétérocycle aromatique monocyclique à 5 chaînons ou à 6 chaînons qui contient un ou deux hétéroatomes identiques ou différents dans le noyau, de la série N, O et S ;</claim-text>
<claim-text>n vaut 0 ou 2 ;</claim-text>
<claim-text>X est un atome d'oxygène ;</claim-text>
<claim-text>sous toutes ses formes stéréoisomères et leurs mélanges en toutes proportions, et</claim-text>
<claim-text>ses sels physiologiquement acceptables ;</claim-text>
<claim-text>où seulement deux groupes nitro au maximum peuvent être présents dans un composé de formule I.</claim-text></claim-text></claim-text></claim><claim id="c-fr-01-0002" num="0002"><claim-text>Composé de formule I selon la revendication 1, dans lequel<br/>
A<sup>1</sup> est un résidu hétéroarylène divalent qui peut être non substitué ou substitué par un ou plusieurs substituants identiques ou différents de la série halogène, alkyle en C<sub>1</sub>-C<sub>4</sub>, CF<sub>3</sub>, -O-alkyle en C<sub>1</sub>-C<sub>4</sub> et -CN ;<br/>
le noyau A<sup>2</sup>, qui comprend les deux atomes de carbone qui portent les groupes R<sup>2</sup>-SO<sub>2</sub>-NH et C(=X)-NH-, est un noyau benzène ;<br/>
R<sup>1</sup> est NR<sup>5</sup>R<sup>6</sup> ;<br/>
R<sup>2</sup> est un groupe aryle ;<br/>
R<sup>3</sup> désigne un ou plusieurs résidus identiques ou différents de la série hydrogène, alkyle en C<sub>1</sub>-C<sub>3</sub>, halogène, alcoxy en C<sub>1</sub>-C<sub>3</sub> et CF<sub>3</sub> ;<br/>
<!-- EPO <DP n="75"> -->R<sup>5</sup> et R<sup>6</sup>, conjointement avec l'atome d'azote portant les radicaux R<sup>5</sup> et R<sup>6</sup>, forment un hétérocycle saturé à 5 chaînons, à 6 chaînons ou à 7 chaînons qui, en plus de l'atome d'azote portant les groupes R<sup>5</sup> et R<sup>6</sup>, peut contenir un autre hétéroatome dans le noyau, de la série N, O et S, et qui peut être substitué par un ou plusieurs résidus identiques ou différents de la série alkyle en C<sub>1</sub>-C<sub>3</sub>, hydroxyalkyle en C<sub>1</sub>-C<sub>3</sub>, aryle, carbamoyle, hydroxy et oxo ;<br/>
le groupe aryle est un groupe phényle ou hétéroaryle, tous pouvant être substitués par un ou plusieurs substituants identiques ou différents de la série halogène, alkyle en C<sub>1</sub>-C<sub>4</sub>, phényle, CF<sub>3</sub>, NO<sub>2</sub>, -O-alkyle en C<sub>1</sub>-C<sub>4</sub>, alkylène(en C<sub>1</sub>-C<sub>2</sub>)dioxy, NH<sub>2</sub>, -NH-CO-(alkyle en C<sub>1</sub>-C<sub>4</sub>), -CN, -CO-NH<sub>2</sub>, -CO-OH et -CO-O-(alkyle en C<sub>1</sub>-C<sub>4</sub>);<br/>
les groupes hétéroaryle et hétéroarylène sont un résidu d'un hétérocycle aromatique monocyclique à 5 chaînons ou à 6 chaînons qui contient un ou deux hétéroatomes identiques ou différents dans le noyau, de la série N, O et S ;<br/>
n vaut 2 ;<br/>
X est un atome d'oxygène ;<br/>
sous toutes ses formes stéréoisomères et leurs mélanges en toutes proportions, et ses sels physiologiquement acceptables.</claim-text></claim><claim id="c-fr-01-0003" num="0003"><claim-text>Composé de formule I selon la revendication 1 et/ou la revendication 2, dans lequel A' est un résidu divalent de pyridine, thiazole ou thiophène, sous toutes ses formes stéréoisomères et leurs mélanges en toutes proportions, et ses sels physiologiquement acceptables.</claim-text></claim><claim id="c-fr-01-0004" num="0004"><claim-text>Composé de formule I selon une ou plusieurs parmi les revendications 1 à 3, dans lequel A' est un résidu hétéroarylène à 5 chaînons sous toutes ses formes stéréoisomères et leurs mélanges en toutes proportions, et ses sels physiologiquement acceptables.</claim-text></claim><claim id="c-fr-01-0005" num="0005"><claim-text>Composé de formule I selon une ou plusieurs parmi les revendications 1 à 4, dans lequel A<sup>1</sup> est un résidu divalent de thiazole, sous toutes ses formes stéréoisomères et leurs mélanges en toutes proportions, et ses sels physiologiquement acceptables.<!-- EPO <DP n="76"> --></claim-text></claim><claim id="c-fr-01-0006" num="0006"><claim-text>Composé de formule I selon une ou plusieurs parmi les revendications 1 à 5, dans lequel le noyau A<sup>2</sup>, qui comprend les deux atomes de carbone qui portent les groupes R<sup>2</sup>-SO<sub>2</sub>-NH et C(=X)-NH-, est un noyau benzène, sous toutes ses formes stéréoisomères et leurs mélanges en toutes proportions, et ses sels physiologiquement acceptables.</claim-text></claim><claim id="c-fr-01-0007" num="0007"><claim-text>Composé de formule I selon une ou plusieurs parmi les revendications 1 à 6, dans lequel<br/>
R<sup>1</sup> est NR<sup>5</sup>R<sup>6</sup> ;<br/>
R<sup>5</sup> et R<sup>6</sup>, conjointement avec l'atome d'azote portant les radicaux R<sup>5</sup> et R<sup>6</sup>, forment un hétérocycle saturé à 5 chaînons, à 6 chaînons ou à 7 chaînons qui, en plus de l'atome d'azote portant les groupes R<sup>5</sup> et R<sup>6</sup>, peut contenir un autre hétéroatome dans le noyau, de la série N, O et S, et qui peut être substitué par un ou plusieurs résidus identiques ou différents de la série alkyle en C<sub>1</sub>-C<sub>3</sub>, hydroxyalkyle en C<sub>1</sub>-C<sub>3</sub>, aryle, carbamoyle, hydroxy et oxo ;<br/>
n vaut 2 ;<br/>
sous toutes ses formes stéréoisomères et leurs mélanges en toutes proportions, et ses sels physiologiquement acceptables.</claim-text></claim><claim id="c-fr-01-0008" num="0008"><claim-text>Composé de formule I selon une ou plusieurs parmi les revendications 1 à 7, dans lequel<br/>
R<sup>1</sup> est NR<sup>5</sup>R<sup>6</sup>;<br/>
R<sup>5</sup> et R<sup>6</sup>, conjointement avec l'atome d'azote portant les radicaux R<sup>5</sup> et R<sup>6</sup>, forment un hétérocycle de la série morpholine, thiomorpholine, 1,1-dioxo-thiomorpholine, 1-oxo-thiomorpholine et diméthylmorpholines;<br/>
n vaut 2 ;<br/>
sous toutes ses formes stéréoisomères et leurs mélanges en toutes proportions, et ses sels physiologiquement acceptables.</claim-text></claim><claim id="c-fr-01-0009" num="0009"><claim-text>Procédé de préparation d'un composé de formule I selon une ou plusieurs parmi les revendications 1 à 8, comprenant la transformation d'un acide aminocarboxylique<!-- EPO <DP n="77"> --> cyclique de formule Il en acide sulfonylaminocarboxylique de formule III, et la transformation du composé de formule III en composé de formule I,
<chemistry id="chem0016" num="0016"><img id="ib0017" file="imgb0017.tif" wi="156" he="65" img-content="chem" img-format="tif"/></chemistry>
ou la transformation d'un acide nitrocarboxylique cyclique de formule IX en un composé nitrocarboxamide de formule XII, et la transformation du composé de formule XII en un composé de formule I par réduction du groupe nitro en groupe amino, et sulfonylation du groupe amino,
<chemistry id="chem0017" num="0017"><img id="ib0018" file="imgb0018.tif" wi="148" he="70" img-content="chem" img-format="tif"/></chemistry>
où, dans les formules I, II, III, IX et XII, les groupes A<sup>1</sup>, A<sup>2</sup>, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> et X et n ont les significations données dans les revendications 1 à 8 ou bien des résidus ou des<!-- EPO <DP n="78"> --> groupes fonctionnels peuvent aussi être présents sous forme protégée ou sous forme de groupes précurseurs.</claim-text></claim><claim id="c-fr-01-0010" num="0010"><claim-text>Composé de formule I selon une ou plusieurs parmi les revendications 1 à 8 et/ou ses sels physiologiquement acceptables à utiliser comme produit pharmaceutique.</claim-text></claim><claim id="c-fr-01-0011" num="0011"><claim-text>Préparation pharmaceutique, qui comprend un ou plusieurs composés de formule I selon une ou plusieurs parmi les revendications 1 à 8 et/ou leurs sels physiologiquement acceptables et un véhicule pharmaceutiquement acceptable.</claim-text></claim><claim id="c-fr-01-0012" num="0012"><claim-text>Composé de formule I selon une ou plusieurs parmi les revendications 1 à 8 et/ou ses sels physiologiquement acceptables à utiliser comme activateur de guanylate cyclase soluble.</claim-text></claim><claim id="c-fr-01-0013" num="0013"><claim-text>Composé de formule I selon une ou plusieurs parmi les revendications 1 à 8 et/ou ses sels physiologiquement acceptables à utiliser en thérapie ou en prophylaxie de maladies cardiovasculaires, de dysfonctionnement endothélial, de dysfonctionnement diastolique, d'athérosclérose, d'hypertension, d'angine de poitrine, de thromboses, de resténoses, d'infarctus du myocarde, d'apoplexies, d'insuffisance cardiaque, d'hypertonie pulmonaire, de dysfonctionnement érectile, d'asthme bronchique, d'insuffisance rénale chronique, de diabète ou de cirrhose du foie, ou pour améliorer les performances mnésiques ou la capacité d'apprentissage limitées.</claim-text></claim></claims><copyright>User acknowledges that Fairview Research LLC and its third party providers retain all right, title and interest in and to this xml under applicable copyright laws.  User acquires no ownership rights to this xml including but not limited to its format.  User hereby accepts the terms and conditions of the Licence Agreement</copyright></patent-document>
